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Phosphate-dependent glutaminase (PDG) is a key enzyme in several physiological processes and 
hence has become a target of anti-cancer drug development because of the role of glutamine in 
providing energy for rapidly dividing cells. This study investigated the effects of the Centella 
asiatica and Catharanthus roseus leaf extracts on enzymes of glutamine catabolism in human colon 
carcinoma (Caco-2) cell line and in enterocytes from Sprague-Dawely rats both treated with plant 
extracts. Our hypothesis was that these extracts would arrest the growth of Caco-2 cells by 
inhibiting glutaminase but have less deleterious effects on normal cells due to the former being 
more avid consumers of glutamine. The 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay was used to assess the cytotoxic effects, and hence the anti-cancer potential 
of extracts from medicinal plants C. asiatica and C. roseus against Caco-2 and human embryonic 
kidney (HEK 293) cell lines. These in vitro effects were assessed using various doses of plant 
extracts (0- 16 mg/ml) and different exposure periods of 24, 48 and 72 h. Results show that the 
cytotoxicity effect of the C. asiatica extract to the caco-2 cell line is dose dependent whilst C. 
roseus treatment decreased the Caco-2 cells viability at all the exposure times but this was not 
dose-dependent. In contrast, both extracts significantly increased cell proliferation of the HEK 293 
cells compared to the controls. The PDG and ALT activities were decreased in Caco-2 cells whilst 
the HEK293 cells were largely unaffected. In the in vivo studies, the activities of phosphate-
dependent glutaminase (PDG), glutamate dehydrogenase (GDH), aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) were determined in the enterocytes. Results show that 
the activities of GDH remained constant whilst there was a decrease in ALT and a slight increase 
in AST activities in the enterocytes in both the C. asiatica and C. roseus treated groups. The PDG 
enterocytes activity, on the other hand, was lower in both the treated groups compared to the control 
group. Expression of both PDG and AST assessed by dot blots in the enterocytes increased in both 
plant extract treated groups. Induction of apoptosis was also investigated using cytochrome c. The 
plant extracts were screened for presence of phytocomponents that may be causing changes in 
Caco-2 cell growth and in enzymes of glutamine catabolism using Gas Chromatography-Mass 
Spectrometry (GC-MS) and qualitative phytochemical analysis. The extracts revealed the presence 
of anticancer and many other compounds. We conclude that the both extracts have potent anti-
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Many drugs that are used in modern medicine have been directly isolated from plants or are 
derived  from templates of compounds from plant sources (Coopoosamy and Naidoo, 2012; 
Jena et al., 2012). Medicinal plants are an important part of the South African cultural heritage 
hence are considered as a health source for the majority of people because of their therapeutic 
properties (Van Wyk et al., 1997). South Africa has an abundance of medicinal plants which 
are used in the traditional treatment of various diseases which include diabetes, intestinal and 
skin disorders, oral, urinary tract infections (UTIs)   (Coopoosamy and Naidoo, 2012). Apart 
from treating physical diseases, medicinal plants are also used to meet the psychological 
health needs in traditional medicine (Iwu, 2014).  
 
Due to the limitations and cost of current anticancer drugs, there is a need to identify safe, 
easily available and effective anticancer drugs to combat and prevent cancer particulary for 
poor communities. Plant extracts are known to contain compounds that possess anti-tumour 
activitiy and some act by hindering the activation of the cell cycle inducing cell death. 
Examples of anticancer drugs isolated from medicinal plants are taxol and vinblastine which 
have been in use for decades (Jena et al., 2012; Pan et al., 2012).  
 
Rapidly dividing cells appear to be addicted to glutamine utilization (Souba, 1993; Medina, 
2001). The cancer cells in culture are avid consumers of glutamine and metabolize glutamine 
at higher rates compared to other amino acids (Erickson and Cerione, 2010). Glutamine is 
said to be a good substrate for oxidation by cancer cell mitochondria hence the high 
glutaminase activity. Tumour cells utilize large quantities of glutamine and compete with the 
host for circulating glutamine simply because glutamine is essential for tumour growth 
(Suzannec Klimberg and McClellan, 1996). The key enzyme that is responsible for initiating 
glutamine oxidation is phosphate-dependent glutaminase (Erickson and Cerione, 2010) but 
the enzyme is also the target of anti-cancer drugs that are being developed (DeBerardinis and 
Cheng, 2010). Since PDG is required for normal cell function  it is important to assess the 
2 
  
effect of anti-cancer medicinal plant extracts and drugs on enzyme in both cancerous and 
normal cells. Not much is known about the effect of medicinal plant species such as 
Catharanthus roseus and Centella asiatica on enzymes of glutamine catabolism in such cells 
hence our study on Caco-2 cell line and enterocytes. 
1.1 What is cancer? 
Cancer is the generic term for a group of diseases characterized by uncontrolled proliferation 
and growth of abnormal cells (Kleinsmith, 2006). Cancer cells divide in a haphazard manner 
in which the balance between cell division and cell differentiation is disrupted when compared 
to normal cells. These cells are large, have irregularly shaped nuclei, prominent nucleoli, large 
nuclear- cytoplasm volume, show variations in shape and cell sizes and visible loss of normal 
tissue organization (Hanahan and Weinberg, 2011). The result is that there is a progressive pile 
up of a non-structured mass called a tumour (Hanahan and Weinberg, 2011; Munoz-Pinedo et 
al., 2012). If the spread is not controlled, it can result in death (Nishida et al., 2006; Crawford 
and Ferrara, 2009). Cancer cells invade surrounding tissues, enter the circulatory system and 
metastasize to distant sites. This invasion is facilitated by decreased cell-cell adhesion, 
increased motility and production of enzymes responsible for degradation of the extracellular 
matrix and basal lamina (Kleinsmith, 2006; Weaver, 2006; Friedl and Alexander, 2011). 
1.2 The causes of cancer 
The known causes of cancer include external factors namely, tobacco use, ionizing and 
ultraviolet radiation exposure etc. (Soto and Sonnenschein, 2010) and internal factors which 
include inherited mutations, viruses and DNA mutations triggered by chemical carcinogens 
(Siegel et al., 2015). These causal factors, illustrated in Figure 1.1,  may act together or in 
sequence to initiate or promote carcinogenesis (Boyle and Levin, 2008). 
 
It is estimated that 15% of cancers diagnosed are a result of hereditary factors (Kleinsmith, 
2006; Hanahan and Weinberg, 2011; Siegel et al., 2015) and 9% are caused by carcinogens in 
the environment (Boyle and Levin, 2008; Soto and Sonnenschein, 2010). A further 5% can be 
attributed to viral infections (Hepatitus B & C / Human Papillomavirus) and 1% can be due to 
other factors (Woodman et al., 2007). Poor lifestyle choices further enhance cancer risks. It is 
documented that 5% of cancers occur as a result of overweight and not getting enough exercise 
(Kolonel et al., 2004), 3% consuming too much alcohol and 20 – 25% using tobacco or tobacco 
products (Proctor, 2001; Siegel et al., 2015). If healthy lifestyles can be adapted, cancer risks 





Figure 1.1:  Pie chart showing causes of cancer as percentages. 
1.2.1 Genetics 
From one generation to the next, abnormal genes can be passed which then ultimately cause 
cancer to give rise to what is referred to as inherited cancer (Kleinsmith, 2006). The cancer 
itself is not inherited but an abnormal gene that leads to cancer is what is inherited (Hanahan 
and Weinberg, 2011). According to (Kleinsmith, 2006; Ferlay et al., 2015) about 5% to 15% 
of all cancers result directly from gene defects (called mutations) inherited from a parent. 
Chemical carcinogens trigger DNA mutations through a multistep process involving initiation 
(DNA mutation), promotion (the initiated cell is stimulated to proliferate) and tumor 
progression (mutations and changes in gene expression create variant cells exhibiting enhanced 
growth rates and aggressive properties (Proctor, 2001; Kleinsmith, 2006; Soto and 
Sonnenschein, 2010; Hanahan and Weinberg, 2011; IARC, 2012). 
1.2.2 Tobacco 
As thoroughly documented, cigarette smoking causes more cancer mortality [death] worldwide 
than any other causative factor (Ferlay et al., 2015; Siegel et al., 2015). Side stream smoke 
(smoke from the lighted end of a cigarette, pipe or cigar) is believed to have higher 
concentrations of cancer-causing agents (carcinogens) and is more toxic than mainstream 
smoke (the smoke exhaled by a smoker) (Proctor, 2001). Tobacco smoke is said to contain a 
mixture of more than 7,000 chemical compounds, 250 of these chemicals are known to be 








































lung cancer, heart disease, worsens asthma and asthma related problems and lower respiratory 
tract infections (Proctor, 2001). 
1.2.3  Sun, UV and Radiation 
Ionizing radiation removes electrons from molecules generating highly reactive ions that create 
DNA damage (Soto and Sonnenschein, 2010). Ultraviolet radiation (UV) causes skin cancer 
by damaging DNA mainly after exposure to sunlight for long hours (Pfeifer and Besaratinia, 
2012). This radiation is absorbed by the skin and triggers the formation of pyrimidine dimer 
which causes distortion of the double helix due to improper base pairing during replication 
(Kleinsmith, 2006; Soto and Sonnenschein, 2010; Hanahan and Weinberg, 2011). For example, 
P53 genes have been shown to be mutated in many human cancers and in skin cancer cells the 
gene shows CC-TT distinctive UV signature (Kleinsmith, 2006). 
1.2.4 Other carcinogens (workplace, pollution and infections) 
Other carcinogens include cancer-causing viruses and infectious agents which act by creating 
tissue destruction thereby indirectly stimulating cell proliferation (You and Jones, 2012). A 
gene whose presence can cause cancer and arises from normal cellular genes called proto-
oncogene by point mutation, gene amplification, local DNA rearrangements and/or insertional 
mutagenesis is called oncogene (Futreal et al., 2004; Hanahan and Weinberg, 2011). On the 
other hand, tumor suppressor genes can lead to cancer when they are lost or inactivated (Futreal 
et al., 2004). 
1.2.5 Obesity and lack of exercise 
Obesity presents a risk to health in the sense that it is associated with an increased risk of 
cancers. In South Africa, there is an alarming increase of individuals who are obese. Obesity 
in women is associated with cancers of the reproductive system i.e. breast, cervix etc. as excess 
body fat results in excess production of oestrogen by adipose stromal cells whereas in men it 
is associated with cancer of the rectum, colon and prostate in men (Futreal et al., 2004; Kolonel 
et al., 2004; Boyle and Levin, 2008; Ferlay et al., 2015).  
1.3 Classification of cancers 
Cancer cells begin to develop in almost any organ. There are several different types of 
categories into which cancers are grouped, depending on the type of cell from which they 





Table 1.1: The major five major categories of cancers. 
Category Origin 
Carcinoma 
Originates in the skin or in tissue that line or cover 
internal organs. For example, breast, prostate, lung and 
colon cancer. 
Central nervous system 
cancers 
Begin in the tissues of the brain and spinal cord. 
Leukemia 
Starts in blood-forming tissue such as the bone marrow 
and causes large numbers of abnormal blood cells to be 
produced and enter the blood. 
Lymphoma and myeloma Originate in the cells of the immune system. 
Sarcoma 
Originates in supportive and connective tissues such as 
bones, cartilage, fat, muscle and blood vessels. 
 
1.4 Epidemiology: cancer and its impact 
Cancer is a serious health concern worldwide as it affects all people irrespective of age, gender, 
race as well as socio-economic status. The International Agency for Research on Cancer 
(IARC), in the GLOBOCAN series, reported that every year not less than 11 million people 
are diagnosed as living with cancer world-wide and of this number 100 000 are South Africans 
(Ferlay et al., 2015). It is estimated that there will be 16 million new cases every year by 2020. 
About 12.5% of all deaths worldwide are caused by cancer (IARC, 2015). Cancers arise with 
differing frequencies in different parts of the world. Japanese  have stomach cancer (Haga et 
al., 2013) whilst in the United States the breast cancer is prominent (DeSantis et al., 2014) and 
liver cancer is common in Africa and Southeast Asia (Khong, 2014; Ladep et al., 2014). Cancer 
has long been the second leading cause of death in the United States following  heart disease 
(Siegel et al., 2015). It accounts for about a quarter of all deaths. With cancer taking such a toll 







Table 1.2: South Africa’s top ten cancers in both the adults and children (non-melanoma 
skin cancers excluded), (National Cancer Registry, 2009). 
SI 
No. 
Top ten Adult Cancers in SA Top ten Children’s Cancers in SA 
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*CUP- means that it is not possible to determine where the cancer originated in the body. LR- 
lifetime risk, TD- total diagnosis. 
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1.5 Colorectal cancer 
The fourth most common type of cancer amongst both South African men and women is  
colorectal cancer (colon cancer). This cancer affects the colon, the large intestine or bowel. 
Colon cancer occurs as a  result of a process whereby  the normal replacement of lining cells 
become abnormal and cause  mucosal cell division mutations to occur (Burkitt, 1977; Parkin 
et al., 2014). Figure 1.2 below show that these mutated cells grow and divide and ultimately 
lead to growths within the colon (polyps) that vary in type i.e. adenomas and hyperplastic 
polyps. These polyps become slow growing precancerous tumours. The growth of 
precancerous tumours through the tube results in the invasion of other layers of the large 
intestine. When this takes place, a cancerous precancerous polyp results 
(http://www.cansa.org.za/files/2015/05/Fact-Sheet-Colorectal-Cancer-May-2015.pdf, 
CANSA, 2015). The National Institute for Occupational Health documented a publication on  
South African cancer statistics showed that cases of colorectal cancer in males and females is 
1295 and 1132 and the lifetime risks of 1:114 and 1:182  respectively 
(http://www.nioh.ac.za/assets/files/NCR_Final_2010_tables(1).pdf). Researchers firmly 
believe that diet and lifestyle play an important role in its prevention. 
 
Figure 1.2: Anatomy of the colon and the stages of colon cancer. Stage 0 - Cancer has grown only 
in the innermost lining (mucosa) of the colon. Stage I - Cancer has grown into the thin muscle 
layer (muscularis mucosa) of the colon. Stage II - Cancer has grown into or through the outermost 
layer and fibrous tissue beneath the thick muscle layer (muscularis propria) of the colon. Stage 
III - Cancer then grows through musclaris propia and it starts to spread to one or more lymph 




1.5.1 Colorectal cancer diagnosis 
Digital rectal examination (DRE) is a physical examination that is commonly used for checking 
lumps inside the rectum (Maas et al., 2015). In about 50-80% cases of colorectal cancer, a 
noticeable rectal lump is found (Hewitt et al., 2003). The DRE is done by placing a well 
lubricated and gloved middle finger into the anus then up into the rectum. Other commonly 
used diagnosis tests are sigmoidoscopy and colonoscopy (Brenner et al., 2014). 
1.6 Cancer management and therapy 
The methods that are currently used for the treatment of cancer include surgery (Kennedy et 
al., 2014), chemotherapy (Mariette et al., 2014), radiation (Milano et al., 2014), hormonal 
therapy (Hait et al., 2015), targeted therapy and immunotherapy (Kleinsmith, 2006). Of all the 
conventional cancer therapy methods, surgery has been the most successful cancer treatment 
for many years and nowadays there are less invasive methods i.e. removing cancerous cells 
whilst the non-affected cells maintain normal functions (Kennedy et al., 2014).  
There are more than 100 chemotherapeutic drugs administered to patients which are often 
distributed throughout the body to reach cancer cells location (Hardin et al., 2012; Mariette et 
al., 2014). These drugs are sometimes combined or used alone (Lane and Chabner, 2009). The 
problem is often their side effects. There are different types of chemotherapy drugs (chemo 
drugs) which are grouped according to how they work, chemical structure and interaction with 
other drugs for example,  alkylating agents, antimetabolites, anti-tumor antibiotics, 
topoisomerase inhibitors, mitotic inhibitors, corticosteroids, miscellaneous etc (Hanahan and 
Weinberg, 2011; Galluzzi et al., 2012). These chemo-drugs only take advantage of the rapid 
division of cancer cells or cell cycle (Chabner and Roberts, 2005). Other drugs and biological 
treatments are used to treat cancer which target properties of cancer cells that are different from 
normal cells. Lastly, there are some other drugs that are given to cancer patients in order to 
stimulate their immune-compromised systems to recognize and attack cancer cells (Luo et al., 
2009).  
An exposure to chemotherapeutic drug results in a situation  wherein the resistant cancer cells 
emerge following treatment. This then calls for approaches that will target proliferating cancer 
cells and leaving the normal cell unaffected. Alternative cancer treatment involves the use of 
medicinal plants that possess anti-tumour activitiy (Jena et al., 2012; Pan et al., 2012). On the 





1.7.1. Role of glutamine in normal mammalian cells 
Glutamine is the most abundant amino acid in the blood, constituting 20-25% of the total 
amino acid pool. Being synthesized de novo from glutamate in the presence of ammonia and 
ATP by glutamine synthetase (E.C 6.3.1.2) (Reaction 1), glutamine plasma concentration 
ranges between 0.6-0.9 mM (Souba, 1993; Medina, 2001) and is about 20 mM in some tissues 
(Souba, 1993). While listed as a non-essential amino acid, it participates as the substantial 
energy source for intestinal epithelial cells as it regulates cell proliferation of the human colon 
and ileum (Windmueller, 1982; Wise and Thompson, 2010). Rapidly dividing cells such as 
intestinal mucosa, lymphocytes, fibroblasts and cancer cells appear to be more reliant to 
glutamine utilization (Souba, 1993; Suzannec Klimberg and McClellan, 1996; 
Papaconstantinou et al., 1998b). According to (Windmueller, 1982; Yoshida et al., 2001; 
Newsholme et al., 2003; DeBerardinis and Cheng, 2010), the principal organs and cells that 
utilize glutamine most are enterocytes of the small intestines, macrophages, kidneys, 
lymphocytes and liver.  
 
Glutamate + NH4
+ + ATP  Glutamine synthetase  Glutamine + ADP + Pi    
(Reaction 1) 
This amino acid is a crucial requirement for synthesis of nucleic acids (purines and 
pyrimidines), proteins and lipids and plays a central role in nitrogen metabolism (Watford, 
2000; Häussinger and Sies, 2012). The skeletal muscle is the main tissue that produces 
glutamine endogenously and has a glutamine concentration of more than 20 mM. It accounts 
for most of the glutamine released into the blood (Pinkus and Windmueller, 1977; Meister, 
1984; Chen et al., 1993; McCauley et al., 1999) (Figure 1.3). Glutamine is essential for 
promoting glucose uptake (Matés et al., 2002), enhancing the hydration state of muscle (Chen 
et al., 1993) and maintaining acid-base homeostasis during intense trainings or workouts 
(Matés et al., 2009). Furthermore, this amino acid is essential for the maintenance of gut 
homeostasis and health (Rhoads and Wu, 2009) as it has beneficial effects such as protection 
of the small intestine from various harmful agents (Pinkus and Windmueller, 1977; Suzannec 
Klimberg and McClellan, 1996), improvement of nitrogen retention and keeping up defences  





Figure 1.3: Illustartion of skeletal muscle as the main source of glutamine, its uptake and fate. 
Adopted from (Souba, 1993).  
 
1.7.2 Role of glutamine in cancer cells 
Since cancer cells are highly proliferating cells, they require a great deal of energy in the form 
of glutamine. They then utilize glutamine more rapidly than the normal cells resulting in rapid 
cancer cells growth as the host glutamine depletion occurs. As the cancerous cells use 
glutamine as a substrate, there is a relative increase in the specific phosphate-dependent-
glutaminase activity (Souba, 1993; Erickson and Cerione, 2010; Nathiya et al., 2012). The 
utilization of  glutamine by cancer cells is directly proportional to phosphate-dependent 
glutaminase activity (Linder-Horowitz et al., 1969; Kovačević and Morris, 1972). Nucleic 
acid and protein synthesis is intensified as well as that of glucose (Suzannec Klimberg and 
McClellan, 1996). Therefore the study of the regulation of glutamine metabolism in cancer 
cells is most crucial as well as the evaluation of its impact in the tumor-bearing state. Cancer 
cells have been reported to have increased glutaminase activity and glutamine synthatase 
inhibition (Erickson and Cerione, 2010; Munoz-Pinedo et al., 2012). 
1.7.3 Glutamine metabolism in the small intestine and cancer cells 
The small intestine plays a key role in digestion and absorption of nutrients. Recent literature 
reveals that the function of the small intestine is much more complex (McCauley et al., 1999; 
Grant et al., 2015). The bowel (multicellular organ) is composed of absorptive enterocytes, 
and other cells namely secretory, immune and neuroendocrine cells that perform a number of 
essential physiological functions including secretion of hormones (Pinkus and Windmueller, 
1977; Petras, 2013). There are three subdivisions in the small intestine, that is, the duodenum, 
jejunum and ileum. The duodenum receives the chime (processed food) in the stomach and 
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is the part of the gastrointestinal tract where  most digestion happens, whereas the jejunum is 
the part of the entire gastrointestinal tract where the most absorption of nutrients occurs and 
the last part of the gastrointestinal tract is the ileum wherein there is some important 
absorption of nutrients that takes place e.g. absorption of vitamins etc. Other organs such as 
liver and gall bladder are said to be important as they deliver bile (composed of bile salts and 
bile pigments) to the duodenum (DeSesso and Jacobson, 2001; Petras, 2013). In addition to 
the above, there is also a pancreas which delivers some important enzymes for digestion 
(Reed and Wickham, 2009). The duodenum has also the brush border enzymes that are very 
important for activation of certain enzymes and for digestion of several nutrients (DeSesso 
and Jacobson, 2001; Reed and Wickham, 2009).  
 
Figure 1.4 shows the wall of the intestine which consists of several layers namely the mucosa, 
submucosa, muscularis and serosa. The mucosa is the epithelial lining that faces the lumen of 
the gut and the connective tissue underlies it. The submucosa, fibrous connective tissue, 
contains blood and lymph vessels as well as nerve networks. Lastly, the muscle layer (also 
called muscularis propia) is covered by the outermost serosa (DeSesso and Jacobson, 2001; 
Petras, 2013). The intestinal wall has numerous infoldings that help increase the  surface area. 
These finger-like projections of the intestinal lining are called villi. The villus  has a lacteal 
which is a specialized lymphatic channel that absorbs and transport nutrients (Petras, 2013). 
Furthermore, electron microscopic examination revealed the presence of more microscopic 
projections in the villi that play a further important function aiding better digestion due to 14 
to 40 fold surface area increase and these are termed microvilli (singular: microvillus) (Reed 
and Wickham, 2009; Petras, 2013). Additionally, there are brush border enzymes which are 
present on the villi and microvilli. The epithelium of the villi and microvilli is lined by a 




Figure 1.4: Anatomy of the small intestine (http://sciencelearn.org.nz). 
 
Glutamine is the most preferred respiratory substrate in the small intestine (Pinkus and 
Windmueller, 1977; Windmueller, 1982; James et al., 1998) and plays a role in the 
functioning and structure of the mucosa. Different organs such as spleen, kidneys, liver, 
pancreas and stomach have been found to utilize circulatory glutamine (Windmueller and 
Spaeth, 1974). Glutamine is taken up in the post-absorptive state by the intestine and other 
organs such as the kidneys which also exhibit net glutamine uptake in the same state 
(Häussinger and Sies, 2012). The metabolism of glutamine in the body occurs by two 
functional pathways (Figure 1.5). The first pathway involves the use of glutamine-derived 
amide nitrogen in amino sugar, purine biosynthesis via glutamine 
phophoribosylpyrophosphate amidotransferase (GPAT) and pyrimidine biosynthesis via 
carbamoyl phosphate synthetase 2 (CPS 2). The second pathway involves the utilization of 
glutamine-derived carbon chain for energy production and α-amino group for the synthesis 
of other amino acids (Windmueller and Spaeth, 1974; Meister, 1984; Watford, 2000; 
Newsholme et al., 2003). The former pathway occurs in the cytoplasm while the latter is 
initiated in the mitochondria (Watford, 1993; Watford, 2000) to produce glutamate the 





Figure 1.5: Pathways and fate of glutamine metabolism in the body. Adapted from 
(Papaconstantinou et al., 1998a; Watford, 2000). 
 
The Figure 1.6 below shows the metabolism of glutamine in the intestinal mucosa where it 
serves as an energy source. Endogenous glutamine from the blood stream enters into the 
mitochondria for energy production. In the intestinal mucosa, glutamine is converted to 
glutamate and ammonia catalysed by the mitochondrial enzyme called phosphate-dependent 
glutaminase (PDG; E.C 3.5.1.2) also known as L-glutamine amidohydrolase as shown in 
reaction 2. The glutamate produced from the glutamine catabolism is converted into α-
ketoglutarate primarily via transamination reactions. During these transamination reactions, 
alanine and aspartate are produced catalysed by alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), respectively. These two transaminases are present in both 
mitochondria and cytoplasm (Masola et al., 1985). The α-ketoglutarate then enters the 
tricarboxylic acid (TCA) cycle where it is oxidized. NADH and FADH2 are produced which 
are then oxidized by the electron transport chain in the mitochondria to synthesize ATP 
(Curthoys and Watford, 1995; Watford, 2000; Newsholme et al., 2003). 
 
Glutamine + H2O 





Figure 1.6: Illustration of glutamine metabolism in the small intestine enterocytes. PDG, 
phosphate-dependent glutaminase; GDH, Glutamte dehydrogenase; ALT, Alanine 
aminotransferase. 
 
Glutamine is taken up by the intestine in the post-absorptive state and its deficiency in the 
intestine leads to intestinal conditions such as diarrhoea, intestinal necrosis, acute necrotizing 
colitis, gut mucosal ulcerations and mild villous atrophy (Papaconstantinou et al., 1998a). 
Therefore, this reinforces the requirement that it should be maintained at a constant 
concentration. (Windmueller and Spaeth, 1974; Watford et al., 2002). Also, it has been 
demonstrated that apoptosis is induced in intestinal cells due to glutamine deprivation 
(Papaconstantinou et al., 1998a). Glutamine can be used as a therapeutic supplement to 
restore and improve health in mammalian cells (Suzannec Klimberg and McClellan, 1996; 
Rao and Samak, 2012). It was further shown that glutamine supplements increase splanchnic 
circulation and reduce mucosal infections as well as restore  the balance between cell death 
and proliferation (Hall and Heel, 1996). There is an ongoing debate whether the traditional 
classification of glutamine as a non-essential amino acid should be re-visited (Watford, 2015).  
 
Cancer cells grow at faster rates thus requiring great amount of energy for continued growth 
and survival. Cancer glutamine metabolism is quite  complicated to study  since there is 
flexibility of the metabolic systems as well as the number of extracellular free nutrients to 
which the cells have access to simultaneously (Erickson and Cerione, 2010; Katt et al., 2012). 
The cancer cells in culture are avid consumers of glutamine and metabolize glutamine at 
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higher rates compared to other amino acids (Souba, 1993; Medina, 2001). Glucose, on the 
other hand, is said to be the major energy fuel playing a crucial role in cancer cell metabolism 
(Vander Heiden et al., 2009) followed by glutamine (Eagle, 1955; Kvamme and Svenneby, 
1960) and both are needed for proliferating cancer cells for bioenergetics and synthesis of 
intermediates for macromolecules (DeBerardinis and Cheng, 2009; Macintyre and Rathmell, 
2013). The Warbug’s effect states that most cancer cells rely aerobic glycolysis to generate 
energy for cellular processes which yields less adenosine 5-triphosphate (ATP). In contrast, 
the normal cells depend on mitochondrial oxidative phosphorylation. Many studies have 
shown that glutamine contributes essentially to most metabolic tasks of proliferating cancer 
cells (Souba, 1993; Medina, 2001; Macintyre and Rathmell, 2013) thus reflecting its 
significant resourcefulness as both the nutrient and mediator of other metabolic processes 
(DeBerardinis and Cheng, 2009).  
 
Cancer cells have large intracellular pools of glutamate (Newsholme et al., 2003) which is 
the product of breakdown of glutamine facilitated by the activity PDG, an enzyme highly 
expressed in cancer cells hence the tumor PDG activity is very high (DeBerardinis and Cheng, 
2009; Erickson and Cerione, 2010; Daye and Wellen, 2012) resulting in sizeable production 
of glutamate. This then highlights the correlaation of PDG activity with tumor growth. 
Experimental designs in which PDG activity was lowered demonstrated decreased growth 
rates of tumor cells (Newsholme et al., 2003). Through the activities of transaminases, 
especially alanine and aspartate aminotransferases, the glutamine’s α-nitrogen is transported 





Figure 1.7: Illustration of glutamine metabolism in cancer cells. Adapted from (Erickson and 
Cerione, 2010). PKM2, The M2 isoform of pyruvate kinase; TCA, Tricarboxylic acid; GLS, 
glutaminase; 968, anti-tumour drug.  
 
There is an increased glutamine metabolism in cancer cells through hydrolysis of glutamine 
to glutamate followed by the subsequent conversion of glutamate to α-ketoglutarate. The 
resulting sizeable α-ketoglutarate is poised to maintain the TCA cycle in cancer cells whereas 
in normal cells pyruvate is converted to acetyl-CoA which then maintains TCA cycle. 
Glycolysis, in cancer cells, results in lactate and its secretion. Another major change is the 
presence of pyruvate kinase isoform (PKM2), an enzyme expressed in cancer cells. This 
pyruvate kinase isoform becomes tyrosine phosphorylated leading to attenuation of pyruvate 
acetyl-CoA conversion (Figure 1.7).  
1.8 Enzymes of glutamine catabolism 
1.8.1 Phosphate-dependent glutaminase (PDG) 
The phosphate-dependent glutaminase (PDG; E.C 3.5.1.2) is the enzyme which hydrolyzes 
glutamine at high rates yielding glutamate and ammonium ions generating the metabolic 
intermediates required for cell growth (shown in Reaction 2)(McCauley et al., 1999). In the 
middle 1980’s, Shapiro and colleagues (Shapiro et al., 1985) studied the orientation of this 
mitochondrial enzyme and  suggested  that it is located in either the matrix or on the inner 
face of the inner mitochondrial membrane. Other studies challenged this idea and concluded 
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that this enzyme is found on the outer face of the inner mitochondrial membrane (Kvamme 
et al., 1991; Roberg et al., 1995; Kvamme et al., 2001). Studies by (Haser et al., 1985; Shapiro 
et al., 1991; Srinivasan et al., 1995) have fully isolated and characterized in vitro expression 
of glutaminase encoding cDNA. 
1.8.1.1 Isoforms of phosphate-dependent glutaminase 
There are two types of glutaminases known as the liver (hepatic) type (LGA) and the kidney 
type (KGA). The kidneys, intestinal epithelial cells, lymphocytes as well as rapidly 
proliferating cells have been shown to express KGA (Curthoys and Watford, 1995; 
Thangavelu et al., 2012) whereas LGA is expressed in the hepatocytes and pancreas (Aledo 
et al., 2000).  Human tissues can simultaneously express both isoforms.(Aledo et al., 2000; 
Campos-Sandoval et al., 2007). There is noticeable 86% similarity in LGA and KGA 
glutaminases amino acid sequence (McCauley et al., 1999), but separate genes encode these 
isozymes. Apparently, the most noticeable difference between the two isoenzymes is that 
KGA is strongly inhibited by glutamate (end-product) whereas the LGA is not inhibited 
(Márquez et al., 2006). 
 
There are two genes that encode the LGA and KGA glutaminases which are located on 
different chromosomes. The KGA gene is found on chromosome 2 whilst the LGA gene 
seems to be located on chromosome 12 (Aledo et al., 2000; Márquez et al., 2006). It is 
believed that glutaminase genes have evolved over time and they have a common ancestral 
gene (Aledo et al., 2000). 
1.8.2 Glutamate dehydrogenase 
Glutamate dehydrogenase (GDH) (EC 1.4.1.3) catalyzes the reversible conversion of 
glutamate to α-ketoglutarate and ammonia (Spanaki and Plaitakis, 2012) using NADP(H) and 
NAD(H) as cofactors. Various tissues such as mammalian liver, brain, kidney, pancreas and 
intestines are known to possess high GDH activity (Fang et al., 2002; Mastorodemos et al., 
2005). In periportal hepatocytes, GDH yields increased quantities of ammonia which are in 
turn utilized for urea synthesis. The GDH activators are ADP and leucine whereas GTP and 
ATP are the inhibitors (Li et al., 2012). During the synthetic reaction (high NADH/NAD+ 
ratio), α-ketoglutarate is converted to glutamate via the GDH action. The resultant glutamate 
can be further converted to glutamine and other amino acids (Frigerio et al., 2008). 
Conversely, at low NADH/NAD+ ratio, the action of GDH results in the production of α-
ketoglutarate which is channelled to the TCA cycle (Frigerio et al., 2008; Li et al., 2012). 
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1.8.3 Alanine and aspartate aminotransferases (ALT and AST) 
Alanine aminotransferase (EC 2.6.1.2) is an enzyme present in tissues such as liver, skeletal 
muscle kidney and heart. It catalyzes a reversible transamination reaction between alanine 
and α-ketoglutarate yielding pyruvate and glutamate (Reaction 3). Aspartate 
aminotransferase (EC 2.6.1.1) catalyzes a reversible transamination reaction between 
aspartate and α-ketoglutarate resulting in oxaloacetate and glutamate (Reaction 4). Two 
isoforms of AST have been reported so far, that is, the cytoplasmic and mitochondrial. 




Alanine + α-Ketoglutarate  Alanine aminotransferase  Pyruvate + Glutamate  
(Reaction 3) 
 
 Aspartate + α-ketoglutarate Aspartate aminotransferase Oxaloacetate + Glutamate 
      (Reaction 4) 
 
1.9 Medicinal plants used in the treatment of cancer 
Medicinal plants have a prehistoric use in the primary health care of individuals. They are 
being used because of their phytoconstituents that are reputed to have curative properties 
(Van Wyk et al., 1997; Howes et al., 2003). Modern medicine utilizes drugs that have been 
primarily derived from medicinal plants (Jena et al., 2012; Street and Prinsloo, 2012) 
implying that plants are primary source of most medicines and still continue to provide new 
remedies. To be effective, some phytoconstituents may be combined with phytoconstituents 
from the same plant or from a different plant for enhancement of the activity of the 
phytocompounds (Howes et al., 2003). The medicinal plant derived extracts aid in healing 
and prevention of various diseases. South Africa is rich in plant biodiversity with over 30 000 
species well documented (Van Wyk et al., 1997; Street and Prinsloo, 2012). Of these about 3 
000 species are used as medicines (Coetzee et al., 1999; Street and Prinsloo, 2012). The 
potential of using plants as anticancer agents was recognized in the 1950s by the U.S. National 




Trichomes are secretory structures found in plants. Early microscopy studies recognized these 
structures are among other anatomical features of plants. These secretory structures differ in 
morphology and arise directly as hairs on the adaxial and abaxial leaf surfaces (Wagner, 
1991). Trichomes have a number of functions (Wagner et al., 2004) including secretion of 
primary and secondary metabolites that are widely used in pharmaceuticals, fragrances, food 
coloring and many more (Van Wyk et al., 1997). Along with medicinal properties, the 
trichomes  are being recognized in plant biology research as a source of essential oil, terpenes 
alkaloids and aromatic biosynthesis.  
 
Examples of  phytoconstituents from medicinally recognized plant species of the genus 
Podophyllum include epipodophyllotoxin known as the active antitumor agent extracted from 
the roots as well as  etoposide, a topoisomerase inhibitor drug class, are widely used in the 
treatment of lung cancer, testicular cancer and leukaemia (Holthuis, 1988)(Figure 1.8). 
Natural products chemists have identified chemical groups from plant species that possess 
antitumor properties, namely: alkaloids, phenylpropanoids, terpenoids, triterpenoids, 
sesquiterpene lactones, flavonoids and coumarins (Wu et al., 2012). Sesquiterpene lactones 
pharmacological activities include cholinergic, hypoglycemic, and anti-inflammatory activity 
and are in species of the Asteraceae, Magnoliaceae and Apiaceae (McKinnon et al., 2014).  
  
 
Figure 1.8: Chemical structures of Etoposide (left) and epipodophyllotoxin (right) from a genus 
Podophyllum. Adapted from (Shi et al., 2001). 
 
1.9.1 Plant species used in this research project 
The two plant species  used for this research were Centella asiatica and Catharanthus roseus. 
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1.9.1.1 Plant classification 
  






Order: Gentianales      Apiales 
Family: Apocynaceae    Apiaceae 
Genus: Catharanthus G. Don      Centella L. 
Species: Catharanthus roseus (L.) G. Don Centella asiatica (L.) Urb. 
 
1.9.1.2 Description of the plant species 
1.9.1.2.1 Centella asiatica 
Centella asiatica (L.) Urban also known as Gotu-Kola and Pennywort, is one of the widely 
used plant species in Malaysia, China, India, Southeast Asia, Sri Lanka and South Africa 
(Brinkhaus et al., 2000; Alfarra and Omar, 2013). Centella has about 50 species and grows 
well in humid conditions. C. asiatica is a small, herbaceous annual plant. The leaves are 
kidney-shaped and sometimes circular, are swaps over and are clustered simultaneously at 
the nodes. C. asiatica has trichomes present in both young and adult leaves. C. asiatica has 
many beneficial effects for human health and has been utilized as a revitalizing herb that 
restores youth and retards aging (Brinkhaus et al., 2000; James and Dubery, 2009). It is 
reputed to strengthen nervous function and memory and treats skin-associated diseases 
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(Orhan, 2012). The herb also prevents dementia and has anticonvulsant, antidiabetic, 
anxiolytic and sedative properties (Rahman et al., 2012). People with mental illness and 
epilepsy are usually given the herb concoction. Previous studies have suggested that C. 
asiatica may have anti-inflammatory effects since it has been used a  as tonic for rheumatism 
and inflammation (Babu et al., 1995; Brinkhaus et al., 2000; Zainol et al., 2003; Bunpo et al., 
2010). The plant’s essential oil is said to contain monoterpenes such as α- pinene, β- pinene 
and γ- terpinene and is reported to inhibit acetylcholinesterase (AChE) (Miyazawa et al., 
1997). Furthermore, phytoconstituents such as alkaloids flavones, triterpenoid, pectin, sterols 
and polyacetylenes are found in C. asiatica extracts. Asiatic acid and medacassic acid have 
been detected and isolated and are known from their therapeutic activities. Also, amino acids 
such as glutamate, alanine, serine have been detected (Howes and Houghton, 2003; Howes et 
al., 2003). In mice, an extract of C. asiatica leaf administered orally at 100 mg/kg increased 
speed rats chronic wound healing. Some other studies conducted regarding the use of C. 
asiatica extracts in treating symptoms of depression and anxiety in Alzhiemer’s disease were 
successful and effective (Howes et al., 2003). In managing epileptic seizure healing, the 
extracts of C. asiatica were found to be proficient (Howes and Houghton, 2003). 
1.9.1.2.2 Catharanthus roseus 
Catharanthus roseus (L.) G. Don, is commonly known as Vinca rosea and Madagascar 
periwinkle. C. roseus has received a lot of attention for its therapeutic abilities in treating 
various kinds of diseases. The plant is native to Madagascar, Caribbean Basin, Europe, India 
and other parts of the world. C. roseus is utilized for conditions such as headache, diabetes 
and to treat various cancers (Farnsworth et al., 1967; Gajalakshmi et al., 2013). C. roseus 
extracts from dried flowers and leaves have been applied to wounds (Nayak and Pereira, 
2006) and the plant has potential efficacy in memory-enhancement (Gajalakshmi et al., 2013). 
C. roseus extracts, amongst other plant  extracts, is also known for its anti-cancer properties 
with no adverse results recorded (Farnsworth et al., 1967; Widowati et al., 2010). It also 
possess hypoglycemic properties (Mohan et al., 2015) thus it is being used for the treatment 
of diabetes.  
Figure 1.10 below shows the Vinca alkaloids in C. roseus. Vinblastine is known in the 
treatment of many forms of leukaemia and has anti-inflammatory effects. Proportionately, the 




Figure 1.10: Chemical structures of Viblastine, R= CH3 and Vincristine, R= CHO which are the 
two major active compounds isolated from C. roseus. 
 
1.10 Phytochemical screening techniques 
1.10.1 Phytochemistry 
Phytochemical tests are used to detrermine the presence of active phytoconstituents such as 
glycosides, terpenoids and steroids, alkaloids, carbohydrates flavonoids tannins and many 
more. Basic laboratory testing methods are done using commercially available stains and 
solutions to detect these compounds (Harborne, 1973; Joshi et al., 2011).  
1.10.2 Gas Chromatography- Mass Spectrometry 
Gas Chromatography – Mass Spectrometry (GC-MS) is a single system as a result of 
integration of gas chromatography as well as mass spectrometry.  Gas chromatography (GC) 
is a partitioning and analysis technique of volatile compounds (McNair and Miller, 2011) 
separating mixture components. There is a mobile phase (carrier gas) and stationery phase 
(liquid or solid). On the other hand, mass spectrometry (MS) provide a plot of mass-to-charge 
ratio (m/z) versus ion abundance produced from sample. A bar graph or table can be used to 
represent mass spectra results. The ion abundance, often in percentages (y-axis), represents the 
number of ions and the mass-charge ratio (x-axis) are separated and detected ions (De 
Hoffmann and Stroobant, 2007). 
1.11 Cell culture studies 
In cell culture, cells are grown under well monitored (controlled) conditions. However, these 
conditions can be manipulated depending on the types of cells grown and their nutritional 
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demands. In vitro studies play a crucial role in testing whether cytotoxicity exists and are then 
followed by animal studies (Li et al., 2004b). The present study employed 3-
4,5dimethylthiazol-2-yl 2,5diphenyltetrozolium bromide (MTT) assay which is a method 
quantifying metabolically viable cells and monitors cytotoxicity (Price and McMillan, 1990) 
to assess whether C. asiatica and C. roseus exhibited any toxicity in the Caco-2 cell lines. 
Nowadays, biomedical research  in different fields including cell biology, drug discovery, 
genetics, HIV testing/treatment, medicine and vaccine development utilizes cell lines before 
a specific drug is passed and administered to animals and human (Li et al., 2004a). 
1.11.1 Cell Viability: MTT assay 
Viable cells reduce a soluble yellow tetrazolium salt (MTT) producing a blue-purple formazan 
crystals catalysed by succinate dehydrogenase (E.C 1.3.5.1), a mitochondrial enzyme. In the 
resultant solution, the formed crystals are dissolved and spectrophotometrically quantified by 
measuring the solution absorbance (Tolosa et al., 2015). 
1.12 Cell lines 
1.12.1 Caco-2 cell line 
Caco-2 cell line (heterogeneous human epithelial colorectal adenocarcinoma) are derived 
from a colon carcinoma as the name suggest.  Under growth conditions, these cells 
differentiate forming a polarized epithelial cell monolayer. Caco-2 cells phenotype, 
morphologically and functionally resembles the enterocytes in the small intestine (Hidalgo et 
al., 1989; Bédrine-Ferran et al., 2004). 
1.12.2 HEK293 cell lines 
HEK293 cells are derived from human embryo kidney cells grown in tissue culture (Ararat 
and Graham, 2002). These cells are widely used for transfection and cytotoxicity studies. 
However, this study used HEK293 cell line for comparative purposes and the enzyme of 
interest which is PDG is also found in the kidneys.  
1.13 Project 
1.13.1 Justification of the present study 
Medicinal plants extracts have proven to be a potential alternative to manage cancer despite 
the current use of conventional anti-cancer drugs such as chemotherapeutic drugs.  The study 
assessed the effect of extracts on Caco-2 cell line growth and viability. This particular cell 
line (Caco-2) was investigated since it is a good model for assessing the effects of anticancer 
drugs and has the ability to differentiate in culture forming a polarized monolayer similar to 
that of the small intestine. Treatments  targeting  this cell line may provide  a  therapeutic 
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strategy for treatment of intestinal cancers and possibly cancers involving other tissues.  PDG, 
an enzyme that has become a focus of anti-cancer drug development was the major object of 
investigation in this project. However, the enzyme is also required for normal enterocyte 
function hence our study not only assessed the effects of the plant extracts on the enzyme in 
Caco-2 cells in vitro but also assesed the effect of the extracts in vivo on rat enterocytes. Other 
downstream enzymes of glutamine catabolism were also investigated as was cytochrome c 
release from cells. 
1.13.2 Aim and Objectives 
Aim: To investigate the effects of Catharanthus roseus and Centella asiatica extracts on 
enzymes of glutamine metabolism in Caco-2 cell line and enterocytes of male Sprague-
Dawley rats. 
Objectives 
1. Evaluate the effect of the extracts on Caco-2 cell line growth and viability as 
indicators of cytotoxicity. 
2. Assessment of the PDG activity and related enzymes in the Caco-2 cell line and in rat 
isolated enterocytes following treatment with medicinal plant extracts. 
Specific objectives 
1. To determine the effect of the plant extracts on Caco-2 cells by performing MTT assay. 
2. To measure the activities of PDG, GDH, ALT and AST in both Caco-2 cell line and 
enterocytes isolated from rats after treatment with medicinal plant extracts using 
enzyme assays. 
3. To determine the effect of medicinal plant extract administration on the expression of 
PDG and AST enzyme using SDS-PAGE Western Blot analysis. 
4. Phytochemical analysis of both C. roseus and C. asiatica extracts using preliminary 
phytochemical screening and GC-MS. 
1.13.3 Research questions 
1. How is cell growth and viability affected after treatment with the plant extract? 
2. Are there any effects of the plant extracts on the glutaminase activity and expression 
in Caco-2 cell lines? 
3. Are there any effects of the plant extracts on the glutaminase activity in enterocytes 
of Sprague-Dawley rats treated with plant extracts? 
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4. Are there any effects of the plant extracts on downstream enzymes of glutamine 
metabolism e.g. aspartate and alanine aminotransferases (ALT and AST)? 
1.13.4 Potential benefits of the project 
The potential benefit is to develop new and alternative sources of drugs for the treatment of 



























Materials and Methods  
 
2.1  Materials 
2.1.1 Chemicals 
The following drugs and chemicals were sourced from SIGMA- ALDRICH (St. Louis, 
Missouri, USA): 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
Acrylamide, Adenosine monophosphate, Benzamidine hydrochloride hydrate, Bovine serum 
albumin (BSA), Bromophenol blue, , Dimethyl sulfoxide (DMSO), Di-Potassium hydrogen 
orthophosphate (K2HPO4), Ethylene diaminetetraacetic acid (EDTA), Methanol (CH3OH), 
N’N’-bis-methylene-acrylamide, Phenylmethanesulfonylfluoride (PMSF), Potassium 
chloride (KCl), Potassium dihydrogen phosphate (KH2PO4), Sodium chloride (NaCl), 
Sodium hydroxide (NaOH), Triton-X 100, TRIZMA base (tris), Tween-20, sodium 
bicarbonate (NaHCO3) and β-Mercaptoethanol. Copper sulphate (CuSO4.H2O), Disodium 
hydrogen phosphate (Na2HPO4), Hydrochloric acid (HCl), Potassium iodide (KI), Potassium 
sodium tartate (KNaC4H4O4.H2O), Sodium hydroxide (NaOH), Sodium sulphate (NaSO4) 
and Sulphuric acid  were purchased from MERCK (Johannesburg, South Africa). 10X 
Tris/Glycine/SDS, N, N, N, N -Tetramethylethylenediamine (TEMED), Sodium dodecyl 
sulphate (SDS), TRIZMA base (tris), Ammonium persulphate (APS) and precision plus 
protein standards (molecular weight marker) we purchased from BIORAD, South Africa. The 
kidney-type glutaminase antibody (KGA) H-45: sc 366447 was bought from Santa Cruz 
Biotechnology, Inc., USA. The secondary antibody Goat anti-Rabbit IgG Alkaline 
phosphatase conjugate were purchased from BIORAD, South Africa. Halothane was from 
Fluorothane® (AstraZeneca Pharmaceuticals, South Africa). Earle’s minimum essential 
medium (EMEM) was from Gibco BRL (Inchinnan, Scotland), Foetal bovine serum were 
purchased from Whittaker Bioproducts (Walkersville, Maryland, USA).  95% Oxygen: 5% 
Carbon dioxide gas was bought from AFROX (South Africa). 
All chemical reagents were of analytical grade and deionized water was used to prepare all 
solutions. 
2.1.2 Animals 
Ethical clearance for animal studies was obtained from the Animal Ethics Committee of the 
University of KwaZulu-Natal (reference 055/14 Animal). 
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Male Sprague-Dawley rats, body weight (230-250 g), were bred and housed in the Biomedical 
Resource Unit (BRU) of the University of KwaZulu-Natal, Westville Campus. For the entire 
experimental period, the animals were maintained under standard laboratory conditions and 
were fed a standard rat chow (Meadows, Pietermaritzburg, South Africa) ad libitum. Also, 
drinking water was provided for all the animals ad libitum. The animals handling rules and 
regulations of the University of KwaZulu-Natal (UKZN) Animal Ethics Committee were 
followed.  
2.1.3 Plant Material 
The Catharanthus roseus and Centella asiatica plant species were harvested from the oval 
residence cricket field around the fence within University of KwaZulu-Natal, Westville 
Campus. Photographic Voucher specimens (Dladla 2) showing plant characteristics was 
prepared and deposited in the Ward Herbarium of the University of KwaZulu-Natal, 
Westville Campus. 
2.2  Methods 
2.2.1 Preparation of extracts 
Leaves of Catharanthus roseus and whole plant of Centella asiatica plant species were 
freshly harvested and air-dried in the laboratory. The dried leaf material was then ground to 
coarse using a mortar and pestle and then to fine powder using Phillips Mini food processor 
with blender (HR7625). The ground material of each plant species was soaked in 1000 ml 
methanol at room temperature for 3 days and overnight at 220 rpm in Infors AG CH- 4103 
BOTTMINGEN shaker (United Scientific, South Africa). Both extracts in the solvent were 
collected separately in pre-weighted glass bottles and filtered using Whattman no.1 paper. 
The resultant filtrates were concentrated to dryness under reduced pressure below 40˚C in a 
rotary evaporator to remove the entire methanol. The dry methanolic extracts were stored 
sealed at 4˚C for further use. 
2.2.2 Experimental Design 
This study involved both in vitro and in vivo experiments (Figure 2.1). In the in vitro studies, 
Caco-2  and HEK293 cells were utilized. These studies evaluated the effects of medicinal 
plant derived extracts on growth and viability using the human colon carcinoma (Caco-2) cell 
line to establish whether the extracts exhibited any toxicity. The cultured cells were treated 
with the plant extracts and the effects of extracts on Caco-2 cell growth and viability 
parameters were determined using MTT assay to measure cytotoxicity (loss of viable cells) 
of potential medicinal agents and toxic materials. The haemocytometer was used to determine 
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the concentration of cells in a liquid sample. HEK293 cells were used as control in the MTT 
assay since they are normal cells derived from kidney and the PDG enzyme is found in the 
kidneys. The in vivo studies investigated the effects of medicinal plant derived extracts on 
PDG and related enzymes in the enterocytes isolated from male Sprague-Dawley rats. Male 
Sprague-Dawley rats treated with extracts were used as the source of enterocytes. Apoptotic 
parameters and enzyme activities were also assessed in enterocytes and a comparison made 
between enterocytes and Caco-2 cells. 
 
In vitro studies     In vivo studies 
 
Figure 2.1: Illustration of the experimental design for both in vitro and in vivo studies. 
2.3  The effects of plant extracts on enterocytes isolated from rats intestines 
Extracts were dissolved in physiological saline (0.9% or 154 mM NaCl). A 15 to 16 gauge 
blunt-ended needle cannula about 11 cm in long (bulbed-end) was used to treat the Sprague-
Dawley rats with the plant  extract. The male Sprague-Dawley rats were divided into three 
groups of 6 rats each, namely; control (CNTRL), Centella asiatica treated (CA) and 
Catharanthus roseus treated (CR). The control group did not receive any treatment but was 
orally dosed with 1 ml of physiological saline. The treatment groups were orally dosed with 
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100 mg/kg CA and CR plant extracts. All the rats were euthanized  14 days following  
treatment and were then used as source of enterocytes. A total of 18 rats (n = 6 per treatment) 
were used for this study to establish if the extracts had any effect over a 14-day treatment 
period in vivo.   
Table 2.1: Representation of the different treatments groups for the in vivo study. 
Male Sprague-Dawley rats 
Groups Control 
n = 6 
C. asiatica 
n = 6 
C. roseus 
n = 6 
Treatments 
(orally) 
1 ml phys. Saline  100 mg/kg 100 mg/kg 
Period 14 days 
Rats euthanized after 14 days treatment period and used as source of enterocytes. 
 
2.3.1 Terminal studies and procedure for isolation of enterocytes 
Enterocytes were prepared using a method by (Watford et al., 1979) modified by (Evered and 
Masola, 1984). Animals were euthanized one at a time using an overdose of halothane (an 
inhalation anaesthetic) in a 2.3L anaesthetic chamber with 2.17 ml/L of halothane 
(Fluorothane®, Astra Zeneca 2002) pharmaceuticals (Pty) LTD for approximately 3 minutes. 
Thereafter the rats were taken out of the chamber and incised on the abdomen. The intestines 
were recovered and the fatty layer around the small intestine was removed. Intestines were 
washed to remove digested residues using medium 1 (118 mM NaCl, 25 mM NaHCO3, 4.7 
mM KCl, 1.18 mM KH2PO4, 1.9 mM MgSO4.7H2O, pH 7.4, saturated with 95% O2 :5% 
CO2). Each intestine was ligated on one end, filled with medium 2 (medium 1 supplemented 
with 5 mM EGTA and 0.25% BSA) and the other end was ligated as well. They were then 
placed in a conical flask containing 250 ml of medium 1. This conical flask was incubated at 
37˚C for 12 minutes in a water bath and was gassed continuously with 95% O2: 5% CO2. 
Medium 2 was removed from the intestines and the intestines were rinsed with medium 1. 
The intestines were then three-quarters filled with ice cold medium 3 (medium 1 
30 
  
supplemented with 0.25% BSA) and ligated on the other end. Enterocytes were detached 
gently by rubbing the intestines along its length using the forefinger and thumb. Once the 
enterocytes were detached, one end of the intestine was unligated and the detached 
enterocytes were released into a clean beaker. 
2.3.2 Homogenate processing 
Enterocytes suspension was divided into four 15 ml centrifuge tubes and centrifuged at 3000 
rpm for 5 minutes using a Hettich Zentrifugen D-7200 Tulttingen bench top centrifuge. The 
supernatant was discarded and the remaining pellet in the centrifuge tubes was washed twice 
with homogenizing buffer containing 50 mM Tris and 120 mM KCl, pH 7.4 with protease 
inhibitors (0.5 mM Benzamidine hydrochloride hydrate and 0.5 mM PMSF).  Enterocytes 
were then homogenized in a buffer using Dounce homogenizer by 7 passes while chilled on 
ice. These were then re-homogenized using a motor driven Glas-Col homogenizer (Terre 
Haute, USA) by 7 passes at 4000 rpm. The homogenates were divided to a total volume of 
15 ml and topped up with 50 mM Tris, 120 mM KCl buffer, pH 7.4 containing protease 
inhibitors. These were then collected into the eppendorf tubes and stored in the deep freezer 
at -20 °C until further use. Some of the homogenate were centrifuged at 10 000 x g for 10 
minutes at 4 °C a using Beckman Coulter J26XPI centrifuge (USA) and both the supernatant 
and pellet were collected and made up to 15 ml volume with homogenizing buffer, pH 7.4. 
These were collected to for assessment of cytochrome c leakage from mitochondria for testing 
apoptotic parameters. 
2.4  Assays of enzymes of glutamine catabolism 
The activities of phosphate-dependent glutaminase, glutamate dehydrogenase, aspartate 
aminotransferase and alanine aminotransferase were assayed. 
2.4.1 Phosphate-dependent glutaminase (PDG) assay 
PDG (EC 3.5.1.2) was assayed at 37°C in a two stage procedure as described by (Curthoys 
and Weiss, 1974) but with modifications (Masola and Zvinavashe, 2003). The amount of 
glutamate produced by PDG was determined through its oxidation by glutamate 
dehydrogenase (GDH). The GDH reaction is accompanied by the reduction of NAD+ to 




Figure 2.2: Phosphate-dependent glutaminase activity assay. 
The assay consisted of solution 1 made up of 10 mM phosphate buffer, 50 mM Trizma base 
and 120 mM KCl and 0.020 M glutamine at pH 7.4. On the other hand, solution 2 had 50 mM 
Tris, 0.31 hydrazine, 2 mM NAD+ and 0.25 mM ADP at pH 9. 50 µl of the enzyme 
(enterocytes homogenate or its fractions) was added to 200 µl Solution 1 (containing freshly 
prepared glutamine to initiate the reaction) and incubated at 37 ˚C for 15 minutes. The 
reaction was stopped by addition of 120 µl of 30% Perchloric acid solution to each test tube 
at intervals of 30 seconds with test tubes being placed on ice for 5 minutes. An aliquot of 225 
µl of cold 3N KOH was added to each test tube to neutralize the acid followed by the addition 
of 2 ml of Solution 2. The test tubes were centrifuged at 3000 rpm (5 minutes) using a Hettich 
Zentrifugen D-7200 bench top centrifuge. Clean test tubes were used to transfer a clear 
supernatant followed by addition of 10 µl GDH enzyme in 50% glycerol (13 U). The test 
tubes were incubated at room temperature for 45 minutes. The absorbance was read at 340 
nm using a Varian Cary 50 UV/Vis Spectrophotometer, USA. 
2.4.2 Glutamate Dehydrogenase (GDH) assay 
A Varian Cary 50 UV/Vis Spectrophotometer, USA fitted with a temperature controlled 
cuvette holder was used to take absorbance measurements at 340 nm. The GDH activity in 
enterocytes was assayed as described by (Schmidt and Schmidt, 1974) by monitoring NADH 




Figure 2.3: Glutamate dehydrogenase assay. 
A buffer consisting of 50 mM Triethanolamine (TEA), 100 mM Ammonium acetate (NH4
+) 
and 2.5 Ethylene diamine tetra acetic acid (EDTA), pH 8 was made. A freshly prepared 7 
mM α-ketoglutarate and 0.2 mM NADH + 1 mM ADP solution were made in buffer and  pH 
adjusted to 8. A 100 µl of enterocytes sample was added to a clean cuvette with 2700 µl TEA, 
EDTA and NH4
+ solution and 100 µl ADP + NADH solution. A 0.1 % Triton-X was added 
to solubilize the enzyme and 10 µl lactate dehydrogenase (LDH) (2.86 units/ml) enzyme was 
also added to remove any interfering pyruvate. The absorbance was read until all pyruvate 
had been consumed and a reaction was started by addition of 100 µl of 7 mM α-ketoglutarate 
in buffer and monitored again at 3-5 minutes. 
2.4.3 Alanine and Aspartate aminotransferase (ALT and AST) assays 
Alanine and aspartate aminotransferases were assayed in coupled assays as described by 
(Volman-Mitchell and Parsons, 1974). Alanine aminotransferase catalyzes the reaction 
between alanine and α-ketoglutarate which generates pyruvate and glutamate. The pyruvate 
produced  is reduced to lactate  catalysed by lactate dehydrogenase (LDH). The LDH reaction 




Figure 2.4: Alanine aminotransferase assay. 
The reaction mixture for ALT consisted of 0.1 M Sodium phosphate buffer pH 7.6 
(NaH2PO4.2H2O and Na2HPO4), 7 mM α-ketoglutarate in buffer, 0.2 mM NADH in buffer 
and 8.6 units/ml LDH in 50% glycerol. A 0.1 ml of sample was then added on a cuvette with 
the above mentioned mixture. After monitoring the non-specific oxidation of NADH, the 
reaction was then started by adding 33 mM L-alanine in buffer in a final reaction volume of 
3ml. On the other hand, aspartate aminotransferase catalyzes the reaction between aspartate 
and α-ketoglutarate which generates oxaloacetate and glutamate. The oxaloacetate produced 
is reduced to malate catalysed by malate dehydrogenase (MDH).  The MDH reaction is 
accompanied by the oxidation of NADH to NAD+ monitored at 340 nm (Figure 2.5). 
 
 
Figure 2.5: Aspartate aminotransferase assay. 
The reaction mixture for AST consisted of 0.1 M Sodium phosphate buffer pH 7.6, 7 mM α-
ketoglutarate in buffer, 0.2 mM NADH in buffer and 19 units/ml MDH in 50% glycerol 
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followed by addition of 0.1 ml of sample. The reaction was started by addition of 33 mM L-
aspartate in buffer after monitoring non-specific oxidation of NADH. 
2.5  The effect of medicinal plant extract administration on the expression of PDG 
enzyme 
2.5.1 Protein Determination 
Protein content of enterocytes was measured using Buiret assay. Bovine serum albumin 
(BSA) was used as a protein standard (Gornall et al., 1949). The biuret reagent consisted of 
3 g of cupric sulfate pentahydrate (CuSO4.H2O) and 9 g of Sodium potassium tartate 
tetrahydrate (KNaC4H4O4.H2O) in 500 ml of 0.2 M Sodium hydroxide (NaOH). A 5 g of 
Potassium Iodide (KI) was added and volume made up to 1 litre with 0.2 M NaOH. A 3 ml 
of the biuret reagent was added to 2 ml of protein sample (enterocytes, supernatant and/or 
pellet sample) in the test tubes. This was  vortexed and incubated for 10 minutes at 37 ⁰C in 
a water bath. The test tubes were left on the bench to cool and centrifuged for 5 minutes using 
the Hettich Zentrifugen D-7200 bench top centrifuge at 1 000 rpm. The absorbance was read 
at 540 nm using a Varian Cary 50 UV/Vis Spectrophotometer, USA. The protein standards 
were plotted against their known protein concentrations in the range of 0-10 mg/ml. A 
standard curve was drawn and the protein concentrations calculated.  
The Lowry method (Lowry et al., 1951) was also used to determine protein concentration. 
Alkaline sodium carbonate reagent (20 g/litre Na2CO3 in 0.1 M NaOH) and copper sulphate-
sodium potassium tartrate solution (5 g/litre CuSO4.5H2O in 10 g/litre Na, K tartate) were 
prepared. A 0.5 ml of sample was added in a test tube containing 5 ml alkaline reagent 
(prepared by mixing alkaline sodium carbonate solution and copper sulphate–sodium 
potassium tartrate solution 50:1) and incubated at 40 °C for 15 min.  Thereafter, the Folin- 
Ciocalteu reagent was freshly prepared by diluting stock 1:2 with deionized water. Samples 
were cooled followed by the addition of 0.5 ml Folin Ciocalteu reagent. These were then 
vortexed and incubated at room temperature for 30 minutes. Using a Varian Cary 50 UV/Vis 
Spectrophotometer, USA, absorbances were read at 600 nm. BSA was used as a standard 




2.5.2 SDS-PAGE and Western Blot analysis 
2.5.2.1 Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was conducted as per instructions in the BIORAD manual. The resolving Gel 
Buffer – 1.5 M Tris-HCl, pH 8.8 and the stacking Gel Buffer – 0.5 M Tris-HCl, pH 6.8. 
Proteins were denatured by heating them in buffer containing sodium dodecyl sulfate (SDS) 
and a thiol reducing agent 2-mercaptoethanol. The resultant denatured polypeptides take on 
a rod-like shape and a uniform charge-to-mass ratio proportional to their molecular weights. 
Proteins were separated according to their molecular weight. The sample proteins were 
separated on a 15% SDS-PAGE gel [2.4 ml (Distilled water) 5.0 ml (30% degassed 
Acrylmide/Bis) 2.5 ml (Gel Buffer) 0.1 ml (10% w/v SDS)] in the presence of sodium dodecyl 
sulphate  using a Bio-Rad Mini - PROTEAN 3 Electrophoresis cell, BIORAD (South Africa). 
The samples were electrophoresed in Tris/Glycine/SDS buffer, pH 8.3 run at 90 V and 
increased to 110 V when the samples have moved through the stacking gel. The gels were 
coomasie stained to visualize the proteins. Proteins were visualized using a Syngene GBOX 
Chem XR5 imager (Vacutec ,South Africa). Images were captured using the GeneSys 
software. 
2.5.2.2 Western-Blot 
Western blot analysis was carried out as follows: The samples containing equal amount of 
proteins were subjected to electrophoresis in 15% (w/v) polyacrylamide gel in the presence 
of sodium dodecyl sulphate (SDS-PAGE) using a Bio-Rad Mini- PROTEAN 3 
Electrophoresis cell (BIORAD, South Africa). A Tris/Glycine/SDS buffer, pH 8.3 was used 
to carry out the electrophoresis at 110 V.  To keep the blotting apparatus cool, an ice cooling 
unit with water was stored in a deep freezer until ready to use.  A Tris/Glycine/Methanol 
transfer buffer pH 8.3 was also prepared. The prepared gel was equilibrated with transfer 
buffer  and the PVDF membrane, filter paper as well as fibre pads were soaked in transfer 
buffer prior the assemblage of the gel sandwich. A Bio-Rad Trans-Blot Electrophoretic 
Transfer Cell (BIORAD, South Africa) assembled with ice-cooling unit, run at 100 V for 2 
hours at 4⁰C in transfer buffer pH 8.3 to transfer the proteins from gel to PVDF membrane. 
The membranes were blocked overnight with 20 mM Tris, 500 mM NaCl, 0.05% Tween 20 
(TBS-T) buffer, pH 7.4 containing 5% (w/v) non-fat dried milk at 4⁰C (which is a blocking 
buffer). The primary IGg rabbit anti-glutaminase antibody was diluted (1: 500) in Tris 
buffered saline containing 0.05% Tween (TBS-T) buffer and overlaid on PVDF membrane 
with shaking for 1 hour at room temperature. Thereafter, the PVDF membrane was washed 
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twice for 10 minutes each  with (Tris-buffered saline) TBS-T buffer and once with blocking 
buffer containing 5% (w/v) non-fat dried milk for 10 minutes. The membranes were probed 
with a secondary antibody Goat anti-rabbit IgG conjugated with alkaline phosphatase, diluted 
1: 1500  in blocking buffer, for 1 hour with shaking at room temperature. Membranes were 
washed thrice for 10 minutes in TBS-T buffer. A substrate, premixed BCIP- NBT solution, 
was used to reveal the antibody-bound proteins. These were then visualized using a Syngene 
GBOX Chem XR5 (Vacutec South Africa), images were captured using the GeneSys 
software and the bands were quantified using GeneTools analysis software. 
Dot blots were conducted as follows: For PDG and AST, 15 µg of proteins from each 
treatment groups were spotted on strrips of PVDF membrane and air dried at room 
temperature. The blocking buffer and probing with antibodies were added for 30 min each. 
Thereafter, the PVDF membranes were washed as described above. A Syngene G-BOX 
Chem XR5 (Vacutec South Africa), was used to visualize the dots blotted.  
2.6  The effect of the plant extracts on caco-2 cells 
2.6.1 Caco-2 and HEK 293 cells 
The Caco-2 and HEK293 cell lines were purchased from Highveld Biological (Johannesburg, 
South Africa). Cell lines came in 25 cm2 flasks (Bibby-Sterilin, Staffordshire, England) at 37 
oC in Earle’s minimum essential medium (EMEM) (Gibco BRL, Inchinnan, Scotland ) 
containing 10% (v/v) foetal bovine serum, 20 mM HEPES, 10 mM NaHCO3, 100 U/ml 
penicillin and 100 µg/ml streptomycin (Whittaker Bioproducts, Walkersville, Maryland, 
USA) at pH 7.5. Cells were divided and stored in a bio-freezer (-80 oC) in complete medium 
containing 10% dimethyl sulphoxide (DMSO). 
2.6.2 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay 
Cell viability was assessed using the MTT assay originally described by (Mosmann, 1983). 
Cells were trypsinized and seeded into 48-well plates (Bibby-Sterilin, Staffordshire, England) 
at a seeding density of 2.4 x 104 cells/well (Caco-2) and 2.8 x 104 cells/well (HEK293) and 
incubated for 24 h to permit attachment and growth of cells to semi-confluency. Thereafter, 
the medium (0.5 mL) was replaced and plant extracts (0, 2, 4, 8 and 16 mg/ml) was added to 
the wells and cells incubated at 37 ºC for 24, 48 and 72 h respectively. After each incubation 
period, the medium was removed and MTT solution (5mg/ml in phosphate buffered saline, 
200 μL) and new medium was added to wells. The cells were incubated for 4 h to allow for 
the formation of blue formazan crystals. The MTT solution was then replaced with DMSO 
37 
  
(200 μl/well) and absorbance measured at 540 nm in a UV-visible spectrophotometer 
(Thermo Scientific Biomate, Cambridge, UK). 
The percentage cell viability was then calculated as follows:  
𝐴𝑏𝑠. 540 𝑛𝑚 (𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠)
𝐴𝑏𝑠. 540 𝑛𝑚 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠)
 𝑥 100  
Technique: Viable cells have active mitochondrial dehydrogenase enzymes which reduce 
MTT dye by cleaving the tetrazolium rings of the pale yellow MTT to form dark blue 
formazan crystal (Bernas and Dobrucki, 2002). These crystals are largely impermeable to cell 
membranes and accumulate within healthy cells. They are also insoluble in an aqueous 
solution but dissolved in DMSO. When DMSO is added, it solubilizes formazan crystals into 
a purple colour. The number of surviving cells is directly proportional to the level of the 
purple formazan product (Bernas and Dobrucki, 2002). This coloured solution can be 
quantified by measuring it’s absorbance at a certain wavelength (between 500 and 600 nm) 
using a spectrophotometer. When the amount of purple formazan produced by cells treated 
with an agent is compared with the amount of formazan produced by untreated cells, the 
effectiveness of the agent in causing death or changing metabolism of cells can be deduced 
through calculation of percentage cell viability using the above mentioned formula. 
2.6.3 Caco-2 cells Protein Determination: Bicinchoninic Acid (BCA) 
Caco-2 cells protein concentration was determined using the BCA method as first introduced 
by (Smith et al., 1985). A working solution was prepared as follows: 49 ml of BCA and 1 ml 
Copper (II) sulfate pentahydrate 4% (w/v) solution. A 0.1 ml of sample and 2.0 ml working 
solution were added in a test tube and mixed well then incubated at 37 ºC for 30 minutes. The 
test tubes were then cooled for 5 minutes and absorbance read at 562 nm. BSA was used as a 
standard range (20 – 100 µg). From the standard curve, the concentration of each sample was 
extrapolated. 
2.7 Phytochemical analysis of the plant extracts 
2.7.1 Gas Chromatography- Mass Spectrometry (GC-MS) 
GC-MS was performed using Perkin Elmer Gas Chromatography Clarus 580 (PE Autosystem 
GC with built-in auto-sampler). For GC-MS detection, an electron ionization system with 
ionization energy of 70 eV was used. Helium was used as a carrier gas at a flow rate of 1.0 
ml/min. The injector and MS transfer line temperature were set at 250 ˚C and 280 ˚C 
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respectively. Oven temperature program was 50-240 ˚C at 5 ˚C min -1. Split ratio was 1:10, 
whereas split flow was 30.7-ml/ min -1.  Mass scan range 50 to 500 amu.  One μl of sample 
(dissolved in hexane 100% v/v) was injected into the system. The relative % of each 
component was calculated by comparing its average peak area to the total area. Software 
adopted to handle mass spectra and chromatograms was a Turbomass.  Interpretation on mass 
spectrum GC-MS was conducted using the database of National Institute Standard and 
Technology (NIST). The name, molecular weight and structure of the components of the test 
materials were ascertained and compound identification was based on the comparison of 
retention indices, mass spectra and the NIST spectrometer data bank as well as comparison 




The phytochemical components were screened by using the methods of (Harborne, 1973; Joshi 
et al., 2011). The phytochemical analyses were solely based on crude extracts obtained above 
and were conducted as follows: 
 
Detection of Alkaloids 
Dragendroff’s test: 2 drops of Dragendroff’s reagent were added to 1 ml of crude extract. 
Formation of reddish/orange precipitate indicates the presence of alkaloids. 
 
Detection of Amino acids and proteins 
Ninhydrin test: 2 drops of Ninhydrin reagent were added to 2 ml of dilute extract. A 
characteristic deep brown colour change indicates the absence of amino acids. 
 
Detection of carbohydrates 
Bennedict’s test: 1 ml of Bennedict’s reagent (Solution 1: made up of 173 g sodium citrate and 
100 g sodium carbonate in 800 ml water, filtered and made up to 850 ml was added to a second 
solution composed of 17.3 g copper sulphate in 100 ml distilled water) was added to 1 ml of 





Molisch’s test: 2 ml of crude extract was added with 2 drops of alcoholic solution of α-naphthol.  
The mixture was shaken well and 1 ml of concentrated sulphuric acid was added along the 
sides of the test tube and allowed to stand.  No violet or purple ring indicates the absence of 
carbohydrates. 
 
Detection of flavones and flavonones 
Aqueous sodium hydroxide: 1.5 ml of extract was added with 1ml of aqueous sodium 
hydroxide solution. Blue to violet colour indicates the presence of anthocynins while yellow to 
orange colour indicates the presence of flavones. An orange-crimson colour change indicates 
the presence of flavanones. 
 
Detection of glycosides, steroids and terpenoids 
Ferric chloride and H2SO4 test: 2.5 ml of extract was mixed with 1 ml glacial acetic acid. 2 
drops of ferric chloride was added followed by the addition of concentrated sulphuric acid such 
that the acid remained underneath. The presence of glycosides is indicated by the formation of 
a brown ring on the junction of the 2 layers and a blue-green ring at the upper surface.  
 
Concentrated Sulphuric acid and chloroform test: 5 ml of the crude extract was mixed with 2 
ml of chloroform. 3 ml of concentrated sulphuric was then carefully added to the mixture 
forming distinct layers. The presence of steroids/terpenoids is indicated by the formation of a 
reddish-brown colour at the interface between the two solutions. 
 
Detection of saponins 
Foam test: 5 ml of extract was diluted with distilled water to 20 ml. About 2 ml was then 
poured in a test tube, for 15 minutes the solution was shaken. The presence of saponins in the 
crude extract is indicated by the formation of a persistence 2 cm foam layer. 
 
 
2.8  Analysis of data 
All results are expressed as mean ± standard error of mean (SEM). Statistical analysis was 
performed using Graph Pad InStat Software (GraphPad ® Prism version 5.0, San Diego, 
California, USA). One-way analysis of variance (1- way ANOVA) followed by Tukey- 
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Kramer multiple comparisons test was used for statistical comparisons of data between 




























3.1  Plant material 
The fine powdered plant species of C. asiatica and C. roseus weighed 2490.80 g and 2703.97 
g, respectively. The resultant dry weight of each of the crude extract after preparation is shown 
in Table 3.1. 
Table 3.1: Dry weight and percentage yield of the medicinal plant extracts. 
Plant species Resultant dry weight Percentage yield 
C. asiatica 102.36 g 4.11 % 
C. roseus 102.38 g 3.79 % 
 
 
3.2 The effect of the plant extracts on Caco-2 cells 
Cell growth and viability Assessment of the anti-cancer potential of extracts from medicinal 
plants Centella asiatica (L.) Urb. and Catharanthus roseus [L] G.D  involved in vitro 
cytotoxic tests against Caco-2 and human embryonic kidney (HEK293) cell lines. Cell 
viability was assessed using the MTT assay. In vitro effects of various doses of plant extracts 
(0, 2, 4, 8, 16 mg/ml) were evaluated in isolated HEK293 and Caco-2 cell lines which were 
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Figure 3.1: The effects of Centella asiatica extract on the cell viability of HEK 293 and Caco-2 cells in vitro after exposure to various concentrations 
of extract for 24, 48 and 72 h. Values are presented as means and vertical bars indicate SEM (n = 3).
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The percentage cell viability of Caco-2 and HEK293 cell lines treated with C. asiatica plant 
extract is shown in figure 3.1. The cell viability of HEK293 cells first increased at 2 and 4 
mg/ml and then decreased at 8 and 16 mg/ml plant extract concentrations after 24 h exposure 
period when compared to the control. After 48 and 72 h exposure periods, the cell viability 
increased significantly and it remained above that of the control. C. asiatica treatment 
significantly decreased (p < 0.05) the cell viability of Caco-2 cells in a dose dependent manner 
after 24, 48 and 72 h exposure periods in comparison to the control. Of note is that, the C. 
asiatica plant extract significantly decreased the cell viability of Caco-2 cells at 8 and 16 
mg/ml concentrations across all three exposure periods. A slight increase in the cell viability 
of both caco-2 and HEK293 cell lines is notable after 24 h exposure at 4 mg/ml plant extract 
concentration when compared to the control. 
 
The percentage cell viability of Caco-2 and HEK293 cell lines treated with C. roseus plant 
extract is shown in figure 3.2 below. The cell viability of HEK293 cells increased at 4 and 8 
mg/ml plant extract concentrations and there was a decrease of cell viability at 16 mg/ml plant 
concentration after 24 h exposure period when compared to the control. Following 48 and 72 
h exposure periods, the HEK293 cell viability increased significantly when compared to the 
Caco-2 cell viability. Of note is that, HEK293 cell viability was below that of the control after 
24 and 48 h C. roseus plant extract treatment whereas after 72 h it remained above that of the 
control. On the other hand, the C. roseus treatment significantly decreased the cell viability 
of Caco-2 cells at different plant extract concentrations (2, 4, 8 and 16 mg/ml) after 24, 48 
and 72 h in comparison to the control. The Caco-2 cell viability remained below 50% or 
slightly higher  across all exposure periods.  
 
Both extracts did not exhibit toxicity to the normal cell line (HEK293) but they significantly 
decreased the viability of the cancer cell line (Caco-2). These results paved the way for in 
vivo studies of the anti-cancer effects of C. asiatica and C. roseus extracts since any use of 
such extracts in treating colon carcinoma or other forms of cancer might also affect PDG 
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Figure 3.2: The effects of Catharanthus roseus extract on the viability and/or metabolic activity of HEK 293 and Caco-2 cells in vitro after exposure 
to various concentrations of extract for 24, 48 and 72 h. Values are presented as means and vertical bars indicate SEM (n = 3).
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Figure 3.3: Effect of C. asiatica and C. roseus on phosphate-dependent glutaminase activity in the Caco-2 cell lines at 2 and 4 mg/ml 
concentrations. Data is represented as means (n = 2). 
 
The PDG activity and related enzymes in the Caco-2 cells were then assessed. The 2 and 4 mg/ml concentration of plant extract were 
chosen because the % cell viability in these concentrations was greater compared to the subsequent plant extract concentrations.  Figure 
3.3 above shows that specific activity of phosphate-dependent glutaminase remained the same at 2 mg/ml and then decreased at 4 
mg/ml following treatment with C. asiatica when compared to the control. Caco-2 cells PDG activity increased at 2 mg/ml after 
treatment with C. roseus. At 4 mg/ml there was a decrease in the PDG activity meaning that both plant extracts decreased PDG activity 
in Caco-2 cells.  
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Figure 3.4 below shows the ALT activity of the Caco-2 cells. The untreated Caco-2 cells had an ALT activity of 68 nmol/NADH 
oxidized/min/mg protein. Treatment with C. asiatica resulted in a decrease of ALT activity in a dose-dependent manner at both 2 and 
4 mg/ml plant concentrations. On the other hand, the ALT activity of Caco-2 cells increased after treatment with C. roseus at mg/ml 













































Figure 3.4: Effect of C. asiatica and C. roseus at 2 and 4 mg/ml plant extract concentrations on ALT activity in the Caco-2 cell line. Data 




3.4  The effect of plant extracts on enterocytes isolated from rat intestines 
Assays on enzymes of glutamine metabolism were then conducted in rat isolated enterocytes. PDG, GDH, ALT and AST assays was 
performed on the three treatment groups, namely; control, C. asiatica and C. roseus. The PDG specific activity was lower in both the 
C. asiatica and C. roseus treatment groups when compared to the control group.  However, the difference was not significant (p > 0.05) 
between all three treatment groups (Figure 3.5). A mean difference of 4.337 and 4.765 was obtained in C. asiatica and C. roseus, 
respectively.  






























Figure 3.5: Phosphate-dependent glutaminase activities in the enterocytes isolated from rat intestines following treatment with 100 mg/kg 




The GDH, ALT and AST activities in homogenates (enterocytes), pellets and supernatants were also performed as shown in Figure 3.6, 
Figure 3.7 and Figure 3.8 respectively. There was no significant difference of the GDH activity in homogenates and pellet fractions (p 
> 0.05). In the case of GDH activity in supernatant fraction, a significant difference was observed in the C. roseus treatment group (p > 




















































Figure 3.6: Glutamate dehydrogenase (GDH) activity in fractions of enterocytes from Sprague-Dawley rats treated with plant extracts. The  
fractions were the homogenate, 10 000 g pellet (mitochondrial fraction) and 10 000 g supernatant (cytosolic fraction). Each data point is 




With the exception of supernatant ALT, there were no significant differences (p > 0.05) in the ALT and AST activities of homogenates, 
pellet and supernatants when compared to the untreated group.  There was a slight increase in the AST activity of the homogenates 
(Figure 3.8). Although the differences remained insignificant, there is a decrease in the ALT activity of the homogenates (Figure 3.7). 
Both the ALT and AST activities revealed reduced levels in the pellets fractions. In the supernatant, the ALT activities show a significant 
difference (p > 0.05) in the C. asiatica group when compared to the control. There was a an increase in the AST activity of the supernatant 


















































                 Enterocyte fractions
 
Figure 3.7: Alanine aminotransferase (ALT) activity in enterocytes fractions from Sprague-Dawley rats treated with plant extracts. The 
fractions were the homogenate, 10 000 g pellet (mitochondrial fraction) and 10 000 g supernatant (cytosolic fraction). Each data point is 
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shown as mean ± SEM (n=6). * p < 0.05 was considered significant, ns means not significant when activities were compared with the 























































Figure 3.8: Aspartate aminotransferase (AST) activity in enterocytes fractions from Sprague-Dawley rats treated with plant extracts. The 
fractions were the homogenate, 10 000 g pellet (mitochondrial fraction) and 10 000 g supernatant (cytosolic fraction). Each data point is 
shown as mean ± SEM (n= 6). ns means not significant when activities were compared with the respective controls. 
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3.5  The effect of medicinal plant extracts on the expression of PDG enzyme 
3.5.1 SDS-PAGE gels 
3.5.1.1 Caco-2 cells 
Figure 3.9 below shows Caco-2 cells protein distribution in a Commassie stained 15% 
polyacrylamide SDS-PAGE gel. The gel shows extremely faint molecular weight proteins in 
Caco-2 cells which are almost undetectable. Due to the little protein content in the Caco-2 cells, 
it was then impossible to carry on with the Western blot analysis. 
       
Figure 3.9: Representative Coomassie stained 15% polyacrylamide SDS-PAGE gel of Caco-2 cells. 
Lane 1: (Molecular weight marker), 2 (Controls), 3 (C. asiatica), 4 (C. roseus). 5 µg of protein was 




3.5.1.2 Rat intestinal enterocytes 
 
Figure 3.10: Representative Commassie stained 15% polyacrylamide SDS-PAGE gels of rat isolated 
enterocytes. Lane 1 (Molecular weight marker), 2 (Control), 3 (C. asiatica), 4 (C. roseus). 50 µg of 
protein was loaded. 
 
3.5.2 Western Blot 
3.5.2.1 Cytochrome c 
 
Figure 3.11: Representative Western blot of Cytochrome of rat isolated enterocytes. Lane 1 
(Molecular weight marker), 2 (Control), 3 (C. asiatica), 4 (C. roseus). 100 µg of protein was loaded. 
 
This study attempted to quantify the expression of PDG and AST using western blot since there 
was adequate protein distribution in the samples of enterocytes (Figure 3.10). The problem in 
carrying out the Western blots of PDG and AST related to the antibodies which had low cross-
activity due to aging and this did not allow successful band formation on the PVDF membrane. 
Therefore, strips of PVDF membrane were used to carry out dot blots which allow for 
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concentrated primary antibody loading. On the positive side, the western blot of cytochrome c 
was successful (Figure 3.11). The bands were skewed which did not allow densitometry analysis 
to be possible hence the dot blots were conducted instead. 
3.5.3 Dot Blots 
3.5.3.1 Caco-2 cells 
The effects of C. asiatica and C. roseus on expression of phosphate-dependent glutaminase 
enzyme in Caco-2 cell lines were not studied due to low protein concentrations. 
3.5.3.2 Rat intestinal enterocytes 
 
 
   




























































Figure 3.12: Dot blots (A) of PDG, AST and Cytochrome c. β-actin was used as loading control. 15 
µg of protein was loaded for PDG, AST and β-actin expression studies. Cytochrome c had 5 µg protein 
loaded. Densitometry values were obtained and used to show the expression of PDG (B), AST (C) and 



























The study also investigated the effects of medicinal plant extract administration on the expression 
of PDG and AST enzymes using Dot blot analysis. Induction of apoptosis was also investigated 
using cytochrome c. We used β-actin, a house keeping gene, to normalize the expression of the 
above enzymes. Figure 3.12 intensity of the PDG and AST expression in the C. asiatica and C. 
roseus treated groups increased when compared to the untreated group (indicated in Graph B and 
C). In the Cytochrome c (indicated in graph D) expressions, there was a marginal increase in 
intensities in both the C. asiatica and C. roseus treated groups but these increase was not different 
when compared to respective control.   
3.6 Phytochemical screening 
3.6.1 Phytochemistry 
Table 3.2 below represents the preliminary phytochemical screening of C. asiatica and C. roseus 
methanolic extracts analysed qualitatively. The phytochemical tests showed  the presence of the 
terpenoids, flavones, essential fatty oils, alkaloids, glycosides, saponins and carbohydrates in the 
C. asiatica plant extract. The alkaloids, amino acids and proteins, carbohydrates, flavones, 
glycosides, terpenoids and saponins were all detected in C. roseus plant extract. Flavones and 
















Table 3.2: C. asiatica and C. roseus methanolic leaf extracts preliminary phytochemical 
constituents.  
Phytochemical test Target compounds 
Plant extracts 
C. asiatica C. roseus 
Control    
Dragendroff’s Alkaloids  + + 
Ninhydrin Amino acids + + 
Bennedict’s and Molisch’s Carbohydrates and 
proteins 
+ + 
Aqueous sodium hydroxide  Flavones - + 
Ferric chloride and H2SO4 







Foam test  Saponins - + 
Key: + present, - absent 
3.6.2 GC-MS 
Profiling of C. asiatica and C. roseus extracts was performed by utilizing GC-MS. This analysis 
indicated the presence of sugars, carotenoids, anti-oxidants, saponins, antibacterial, terpenes and 
anti-tumour compounds in both the plant extracts as shown in Table 3. 3 (a and b). The 
chromatography and mass spectra with identified compounds structures are found in the 
appendices (Few compounds structures are not clear due to a problem encounted with the printer). 
A total of 33 phytocomponents were detected in C. asiatica and 36 phytocomponents in C. roseus. 
Table 3.4 presents the identified anticancer phytocomponents that have not been found in both C. 
asiatica and C. roseus leaf extracts  but are known to have anticancer properties. These are marked 


















1 5.41 R-Limonene C10H16O3 0.80 184 
2 5.33 Thiofanox C9H18N2O2S 0.38 218 
3 4.93 Deoxyspergualin C17H37N7O3 0.52 387 
4 4.93 Bemegride methyl 
derivative 
C9H15NO2 0.43 169 
5 4.85 Betaxolol C18H29NO3 0.33 307 
6 4.44 Metoprolol C15H25NO3 0.11 267 
7 4.44 *Iberin C5H9NOS2 0.15 163 
8 5.33 *Chlorozotocin C9H16CIN3O7 0.25 313 
9 4.44 Dihyroxyacetone C3H6O3 32.4 90 
10 5.67 *Desulphosinigrin C10H17NO6S 9.91 279 
11 5.65 3.4 Altrosan C6H10O5 17.1 162 
12 3.86 Aprobarbital C10H14N2O3 0.32 210 
13 3.86 6-Thioguanosine C10H13N5O4S 0.77 299 
14 6.25 *Showdomycin C9H11NO6 0.21 229 
15 8.64 p-Cymen-7-ol C10H14O 1.80 150 
16 3.25 Nonanoic acid C9H18O2 0.55 158 
17 3.25 Undecanoic acid C11H22O2 4.85 186 
18 3.25 Diphenylamine C12H11N 1.40 169 
19 3.25 Pheniramine C16H20N2 15.8 240 
20  1-Penten-3-one C5H8O 30.7 84 
21 14.74 Phytol C20H40O 17.58 296 
22 14.52 Lysergic acid C16H16N2O2 20.03 268 
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23 3.90 Formic acid, 2-
methylhex-3-yl ester 
C8H16O2  7.57 144 
24  Pyrrolizidine-3-one-5-
ol, ethyl ether 
C9H15NO2 9.99 169 
25  Isosorbide dinitrate C6H8N2O8 24.2 236 
26 8.42 Meprobamate C9H18N2O4 0.39 218 
27 6.49 Ropivacaine C17H26N2O 1.40 274 
28 6.56 Guanethidine C10H22N4 0.81 198 
29 6.49 Aceclidine C9H15NO2 1.09 169 
30 8.64 Thymol C10H14O 1.16 150 
31 7.52 β- Eucine C15H21NO2 6.56 247 
32 5.3 *Chlorozotocin C9H16CIN3O7 0.59 314 
33 8.64 Ascaridole C10H16O2 1.29 168 
 Are anticancer compounds detected. 
 









1 3.07 Pheniramine C16H20N2 27.1 240 
2 3.07 Diphenylamine C12H11N 5.97 169 
3 3.05 2-p-Tolylpyridine C12H11N 1.34 169 
4 3.67 Norpheniramine acetate C17H20N2O 0.25 268 
5 3.67 *Hydrazinecarboxamide, 
N,N-diphenyl- 
C13H13N3O 3.99 227 
6 3.19 Glycyl-l-glutamine C3H13N3O4 0.73 203 
7 3.22 Cyclopentobarbital C12H14N2O3 0.35 234 
8 3.24 (S)-(+)-2-Amino-3-
methyl-1-butanol 
C5H13NO 6.48 103 
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9 4.34 Secobarbital C12H18N2O3 0.29 238 
10 7.69 Valeric acid, 2-tetradecyl 
ester 
C19H38O2 5.08 298 
11 7.69 Tetrahydropyranyl ether of 
citronellol 
C15H28O2 1.03 240 
12 7.82 Maltol C6H6O3 0.09 126 
13 7.82 5-Hydroxymethylfurfural C6H6O3 27.9 126 
14 7.82 Spiro[cyclohexanol-3-2΄-
hexahydropyridine] 
C10H19NO 4.12 169 
15 7.98 3΄-
Hydroxyquinalbarbitone 
C12H18N2O4 23.3 254 
16 7.98 Talbutal C11H16N2O3 0.43 224 
17 7.98 Kainic acid C10H15NO4 0.27 213 
18 7.98 Thiamylal C12H18N2O2
S 
0.26 254 
19 7.98 Butabital C11H16N2O3 0.40 224 
20 8.60 Pyrrolizidine-3-one-5-ol, 
ethyl ether 
C9H15NO2 13.6 169 
21 8.49 Oleic acid C18H34O2 1.17 282 
22 10.30 Nonanoic acid C9H18O2 0.50 158 
23 8.60 p-Cymen-7-ol C10H14N 1.04 150 
24 8.65 D-Verbenone C10H14O 0.92 150 




C11H14N4O5 25.0 282 
27 9.80 *Psicofuranine C11H15N5O5 0.11 297 
28 9.80 Albuterol C13H21NO3 0.12 239 
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29 10.56 *Desulphosinigrin C10H17NO6S 4.10 279 
30 10.22 Solasonine C45H73NO16 0.66 883 
31 10.30 Stevioside C38H60O18 3.79 804 
32 10.30 Curan-17-oic acid, 19,20-
dihydroxy-, methyl ester, 
(19S) 
C20H26N2O4 0.39 358 
33 10.30 Erucic acid C22H42O2 0.25 338 
34 10.30 β-Sedoheptitol C7H16O7 0.58 212 
35 10.30 Thiofanox C9H18N2O2S 0.49 218 
36 10.30 3.4 Altrosan C6H10O5 0.49 162 




















Table 3.4: Anticancer compounds detected by GC-MS but not previously identified in C. asiatica 
and C. roseus extracts. 



























The aim of the current project was to investigate the effects of C.  roseus and C. asiatica leaf 
extracts on enzymes of glutamine catabolism in Caco-2 cell line and in enterocytes from male 
Sprague-Dawley rats. The study first investigated the effects of the medicinal plant leaf extracts 
on cell growth of the Caco-2 cells in order to stablish whether they exhibit any cytotoxicity towards 
cancer cells. Secondly, the effects of C. roseus and C. asiatica leaf extracts on enzymes of 
glutamine catabolism were also assessed in Caco-2 cells and enterocytes from rat intestines. 
Furthermore, this project reports on some phytochemical analysis of both  C. roseus and C. asiatica 
medicinal plant leaf extracts using preliminary phytochemical screening and GC-MS to detect the 
presence of active compounds making these plant species widely utilized as anticancer agents. 
GC-MS identified the compounds that may be responsible for changes in cell growth as well as 
changes in enzymes that could underpin the alterations in cell growth.  
 
The MTT assay results obtained from this present study indicate that the cytotoxicity effects of C. 
asiatica leaf extract to Caco-2 cell line was dose-dependent (Figure 3.1) whilst that of C. roseus 
was not dose dependent (Figure 3.2) as indicated by cell viability. Both the leaf extracts have 
anticancer potential since they did not exhibit toxicity to the normal cell line (HEK293) but they 
significantly decreased the viability of the cancer cell line (Caco-2). Previous studies reported that 
cell cycle arrest was induced in Caco-2 cells following treatment with C. asiatica  (Bunpo et al., 
2010). It was also reported that the proliferation rate of the Caco-2 cells was significantly reduced 
(Bunpo et al., 2010) in a manner similar to that reported in this present study in which the reduction 
in growth is concentration and time dependent (Figure 3.1). El-Sayed and Cordell also isolated a 
new antitumor alkaloid, catharanthamine, from C. roseus and they found that this novel alkaloid 
was cytotoxic in the KB test system in vitro and displayed significant activity in the P-388 
lymphocytic leukemia test system (El-Sayed and Cordell, 1981).  The ideal anticancer therapy is 
the one that targets the proliferative cancerous cells and leaves the normal cells unaffected 
following therapy. The HEK293 cell line was used in this study as a control since it is derived 
from normal cells. This cell line is ideal and suitable for the investigation since the enzyme of 
interest is also found in kidneys. Treatment with C. asiatica and C. roseus at different plant extract 
62 
  
concentrations in different exposure times left the HEK293 cells unaffected and their viability was 
stimulated. 
 
Cancer cells are consumers of glutamine in culture and they require it as an energy source to 
maintain their proliferative abilities (Rajagopalan and DeBerardinis, 2011). Deamination of 
glutamine to glutamate catalysed by PDG, an enzyme found in mitochondria, play an important 
role in providing energy to highly proliferative cells including the enterocytes (Windmueller and 
Spaeth, 1974). It has been reported that cancer cells require a great deal of energy in the form of 
glutamine and hence there is high PDG activity observed (Rajagopalan and DeBerardinis, 2011).  
In this study, we hypothesized that treatment with the extracts would arrest the growth of Caco-2 
cells by inhibiting PDG activity but have less deleterious effects on normal cells. The results in 
this study show that the activity of PDG was decreased following treatment with plant extracts 
especially at 4 mg/ml (Figure 3.3). The C. roseus and C. asiatica plant extracts inhibited PDG 
significantly hence depriving the Caco-2 cells of an energy source hence the reduced viability of 
the Caco-2 cells. Previous studies have demonstrated that one of the effective means to treat cancer 
is to target their metabolic substrates (Souba, 1993; Medina, 2001). In this case, we focused our 
investigations on a mitochondrial enzyme (PDG) that initiates glutamine oxidation. It is also 
reported that cancer cells rely on mitochondrial respiration to produce ATP, hence mitochondrial 
enzymes generally play a vital role in cancer cell metabolism (Suzannec Klimberg and McClellan, 
1996; Munoz-Pinedo et al., 2012). 
 
When comparing the effects of the extracts on PDG activity in the Caco-2 cell line with the 
enterocytes, the same effects of the extracts were observed wherein there was a decrease in the 
PDG activity of the enterocytes from treated animals compared to those from the normal animals 
(Figure 3.5). However, the drawback in comparisons is that in the in vivo studies, the concentration 
of the plant extract to which the enterocytes are exposed as a result to of the 100 mg/kg oral dose 
is not known unlike that for Caco-2 cells. If the extracts concentrations are similar, then the 
comparisons might show which is affected more because this is important in therapy. The PDG 
activity in Caco-2 cells was 4-fold greater than the PDG activity in the enterocytes in the control 
groups and 3-6 fold in the extracts treated groups. This also reinforces the finding that Caco-2 cells 
rely on glutamine for cellular metabolism to maintain their proliferative state (Clark et al., 2003). 
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The ALT and AST levels have been widely used as biomarkers of cellular damage (Sherman, 
1991; Mukorah et al., 1998; Masola et al., 2003) and are more important in the glucose and amino 
acids metabolism. Hernaez and colleagues evaluated the relationship between liver enzymes, 
particularly the ALT and AST, and cancer mortality. They found that these enzyme levels were 
highly elevated in serum in Taiwanese males indicating a positive association or increased cancer 
risk (Hernaez et al., 2013). In the in vitro studies, an increase in ALT activity was seen at 2 mg/ml 
following treatment with the C. roseus which was reduced to control levels by treatment with 4 
mg/ml C. roseus (Figure 3.4). The observed initial increase in ALT activity in Caco-2 cells is 
expected due to increased energy demands as a result of treatment when cell viability is still at 
least 50 % or above at extract concentrations of 2 mg/ml. There was a decrease in ALT activity at 
both concentrations (2 and 4 mg/ml) C. asiatica treated Caco-2 cells (Figure 3.4). The observed 
main trend was basically a reduction in the ALT activity for both C. asiatica and C. roseus treated 
Caco-2 cells. The observed trend actually correlates with the reduction in PDG activity which also 
occurs at 4 mg/ml (Figure 3.3). Reduction in PDG activity means that there is no substrate coming 
through to the downstream enzymes. Since ALT is a downstream enzyme and is involved in the 
energy generation, the current in vitro study focused mainly on this specific enzyme and not the 
AST and GDH. In the intestines, alanine is released as the main amino acid product of glutamine 
oxidation, therefore, it was important to investigate this transamination reaction. However, with 
hindsight, AST and GDH should also have been investigated but cell material we had to work with 
was limited. 
 
The effect of plant extracts on downstream enzymes of glutamine catabolism in enterocytes from 
rat intestines was assessed particularly GDH, ALT and AST. The changes in GDH activities were 
not significant (Figure 3.6) and there was a decrease in ALT activity (Figure 3.7) whilst the AST 
saw a slight increase (Figure 3.8) in the homogenates following treatment with both plant extracts. 
These are the downstream enzymes of glutamine metabolism and are involved providing substrates 
for the TCA cycle in energy generation. As the enterocytes were treated with the plant extract, a 
stress occurred resulting in increased energy demands hence the reduced levels of ALT. AST  is 
mainly involved in generating aspartate for nucleotide synthesis that is why this particular 
downstream enzyme was slightly activated in enterocytes.  
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The preliminary phytochemical tests revealed the presence of different plant chemical constituents 
in both C. asiatica and C. roseus methanolic extracts, as shown in Table 3.2, which were also 
shown in previous studies (Rahman et al., 2012; Mohan et al., 2015). Chemical profiling of both 
the methanolic C. asiatica and C. roseus plant extracts by GC-MS indicated the presence of 
phytocomponents such organic acids, alcohols, amino compounds, sugars and monoterpenoids and 
these were also previously reported (Apichartsrangkoon et al., 2009; Sudha et al., 2011; Mohan et 
al., 2015). Thirty three and thirty six compounds of leaf extracts of C. asiatica and C. roseus, 
respectively, have been identified. Both plant species, since prehistoric times, they have been 
widely used for their therapeutic properties.  
 
The identified phytochemicals in C. asiatica include showdomycin and altrosan which are 
antibiotics that inhibits bacterial growth (bacteriostat). Previous studies have investigated the 
antibacterial activities of this plant species (Brinkhaus et al., 2000; Oyedeji and Afolayan, 2005; 
James and Dubery, 2009). C. asiatica has also been found to have sedative, anticonvulsant, 
anxiolytic and hypnotic properties (Inamdar et al., 1996; Brinkhaus et al., 2000). Aprobarbital 
which is an anticonvulsant, sedative and hypnotic drug, a lysergenic acid, an alkaloid used as 
psychedelic drug that improves consciousness and promotes physical and mental healing as well 
as meprobamate which is an anxiolytic drug have been identified in this present study. C. asiatica 
is regarded as plant with an ability to improve memory (Nalini et al., 1992; Heidari et al., 2012). 
Metoprolol and isosorbide dinitrate have been used to treat chest pain and angina. These were also 
detected in this C. asiatica plant extract.  
Anticancer properties of this plant species are well documented (Babu et al., 1995; Lee et al., 2002; 
Bunpo et al., 2004; James and Dubery, 2009; Heidari et al., 2012). The current study detected the 
presence of iberin (induces apoptosis in cancer cell lines, promotes expression of antioxidant and 
detoxification enzymes), chlorozotocin (used in cancer therapy) and desulphosinigrin (anti-cancer 
drug). Desulphosinigrin, in particular has been reported to be a new anticancer drug target 
(Krishnaveni, 2015). Furthermore, many more phytochemicals were detected by GC-MS including 
the following; R-limonene (a cyclic terpene), aceclidine and betaxolol used for narrow angle 
glaucoma and hypertension treatment). 6- Thioguanosine (leukemias treatment drug and ulcerative 
colitis), nonanoic acid (a carboxylic acid used for treatment of seizures), pheniramine 
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(anticholinergic, treats allergic conditions). Phytol, ascaridole and thymol are acyclic diterpene 
used in manufacturing of vitamin E and K1, bicyclic monoterpene and monoterpene respectively. 
Also, β-eucaine and ropivacaine (anaesthetic drugs), p-cymene also known as cuminol (essential 
oil, powerful antioxidant) (Rahman et al., 2012) and guanethidine (antihypertensive drug) were 
detected (Table 3.2.1a). 
 
On the other hand, the C. roseus has been reported to exhibit hypotensive and tranquilizing 
properties (Nayak and Pereira, 2006; Agarwal et al., 2011; Gajalakshmi et al., 2013). The current 
project GC-MS profiling saw the presence of cyclopentobarbital, 3'-Hydroquinalbarbitone, 
thiamylal and secobarbirtal which are drugs having anticonvulsant, anxiolytic anaesthetic and 
sedative properties, hence showing this plant’s pharmacological properties. C. roseus has also 
received  attention due to its ability to treat and prevent cancer as well as its hypotensive abilities 
(Farnsworth et al., 1967; Gajalakshmi et al., 2013). We found the presence of pheniramine, 
hydrazinecarboxymide,N,N-diphenyl- a semicarbazide (antineoplastic, anti-infective and 
antiviral), psicofuramine (antibiotic and antitumor drug) (Evans and Gray, 1959; Slechta, 1960) 
which may be responsible for the plant being used in cancer treatment. Amongst other world-wide 
problems is the occurrence of parasitic worms that feed on the host thereby causing intracellular 
damage to the host (Fumagalli et al., 2010). The kainic acid, an antiworming agent (anthelmintic) 
as well as a neuroexcitatory amino acid have been detected in the current phytocomponent 
analysis. The mechanism of action is likely to be targeting the parasitic worm without causing 
damage to the host.  
Other phytocomponents detected in methanolic extracts of C. roseus with  healing abilities include: 
glycyl-glutamine, gly-gln (inhibits cardiovascular and respiratory depression)(Cavun et al., 2005), 
5-hydromethylfurfural (sickle cell disease treatment), talbutal (schedule 111 drug, induce 
anesthesia), butalbital (headache and pain treatment when combined with other medications such 
as paracetamol), pyrrolizidine-3-one-5-ol, ethyl ether, nonanoic acid (a carboxylic acid used for 
treatment of seizures), p-cymen7-ol also known as cuminol (essential oil, antioxidant), verbenone 
(naturally plant occurring terpene), thymol (natural monoterpene phenol, cymene and carvacrol 
derivative), albuterol also known as Ventolin (bronchodilator, treat wheezing and shortness of 
breath), solasonine (antiproliferative) (Munari et al., 2014). Stevioside is documented to have a 
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wide range of curative properties as a natural sweetener and has antihyperglycaemic, 
antihypertension and antitumor effects (Lee et al., 2001; Jeppesen et al., 2002; Gregersen et al., 
2004; Paul et al., 2012). Lastly, tetrahydropyranyl ether of citronellol a monoterpenoid, used in 
perfumes and as insect repellent as well as maltol (flavour enhancer) were also detected by GC-
MS analysis. 
 
Of particular interest was the presence of phytocomponents that are known to be anticancer 
compounds but have not been previously detected in these plant species and are known to be 
present in other plant species. These phytocomponents are iberin, chlorozotocin and 
desulphosinigrin in C. asiatica as well as showdomycin, hydrazinecarboxymide, N,N-diphenyl- 
and psicofuramine  in C. roseus which are anticancer compounds (Table 3.4). Desulphosinigrin 
was found to be present in both the extracts. Perhaps these anticancer compounds together with 
the other compounds may be contributing to the anticancer properties of these particular plant 
species. With regards to this study, these phytocomponents may be causing changes in Caco-2 cell 
growth and changes in enzymes of glutamine catabolism.  
 
Previous studies have shown that iberin induced cell cycle arrest of some cancer cell lines (Jadhav 
et al., 2007) and was also found in vegetables of the family Brassicaceae (Munday and Munday, 
2004). Chlorozotocin, a nitrosourea and cytostatic agent, that was long discovered and used as an 
antitumor agent (Anderson et al., 1975; Schein et al., 1976) has  been widely utilized in the 
treatment of cancers particularly of the stomach, large intestine, pancreas and lung (Kannan 
Elangovan et al., 2014). Kannan and colleagues also investigated the presence of bioactive 
compounds in the methanolic seed extract of Memecylon umbellatum plant species and their GC-
MS analysis revealed the presence of chlorozotocin (Kannan Elangovan et al., 2014). The current 
project showed presence of desulphosinigrin, which has been documented to be found in Soymida 
febrifuga seeds amongst other plant species and is said to be an anticancer target (Krishnaveni, 
2015). 
 
Previous in vitro cytotoxicity studies revealed that hydrazinecarboxamide, a semicarbazide, had 
antitumor properties when it was synthesized and evaluated against human solid tumor growths 
including human non-small cell lung cancer (H1299), lung adenocarcinoma (CL 1-0 and CL 1-5), 
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prostate cancer (PC-3) and resistant breast cancer (MCF-7) cell growth in vitro (Kakadiya et al., 
2010). Although this was synthesized it was also detected in the GC-MS analysis of C. roseus. 
Lasty, the showdomycin and psicofuramine also act as  antitumor agents and prevent the growth 




























 Firstly, in in vitro studies, cytotoxicity has indicated that C. asiatica and C. roseus plant 
extracts inhibited the growth of Caco-2 cells  and left the normal cells unaffected. This is 
the desirable property of these extracts. 
 The extracts inhibit the key enzyme that initiate glutamine oxidation (PDG) in Caco-2 cells. 
This could be the mechanism for the anticancer properties of these extracts. 
 The extracts also affects downstream enzymes since there was a decrease in PDG in Caco-
2 cells. In normal cells the enzyme PDG was also decreased but there were no drastic 
changes in the downstream enzymes. 
 Great number of compounds were found, as well as   several anticancer compounds were 
detected. However  of particular interest are these particular anticancer compounds which 
have not been previously detected in these plant species namely; iberin, chlorozotocin and 
desulphosinigrin in C. asiatica as well as showdomycin, hydrazinecarboxymide, N,N-
diphenyl- and psicofuramine  in C. roseus. 
 We conclude that these plant extracts have anticancer potential but there is need for further 
studies. 
 This study lends scientific credence and validity to the development of new drugs sources 
from plants for treatment of cancer in humans and reveals the medicinal benefits of 










Potential future studies may focus on the concentration of the identified anticancer compounds in 
the intestinal fluid which will give an indication or level in which the extract reaches the intestine. 
Also, to measure the final extracts concentration the enterocytes will be exposed to following 
dosage so that there is a proper comparison with the cultured cells which are the first line of looking 
at the effects on the enzymes. If the enterocytes are affected less, this will be a breakthrough in 
cancer treatment given that a  critical enzyme, PDG to look at.   
It would be ideal to further test the effects of the C. asiatica and C. roseus in animal that are bearing 





























Appendix 3: Standard curves 
Buiret Assay Standard Curve























Folin-Lowry Assay Standard Curve






















































Appendix 4: PDG activity calculations 
Glutaminase activity = 
∆ Abs.× Reaction vol.(ml)× 1000 × 1000





Glutaminase activity is expressed in: nmoles glutamate formed/min/mg protein  
Key: 
∆ Abs.   = change in absorbance when glutamate is converted to α-ketoglutarate  
Reaction vol.   = Final volume of the reaction mixture in ml  
× 1000 × 1000  = to express the activity in nano moles 
6.22 x 103   = NADH molar extinction coefficient (Moles-1cm-1) at 340 nm  
Time (minutes) = time taken for glutamate dehydrogenase to form β-NADH  
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